Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	B-DNA
enhancer/promoters	I-DNA
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

The	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
contains	O
binding	O
sites	O
for	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O

To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	B-DNA
enhancer/promoters	I-DNA
were	O
inserted	O
into	O
the	O
HIV-1	B-DNA
LTR	I-DNA
in	O
place	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
.	O

The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	B-cell_line
cells	I-cell_line
and	O
on	O
HIV	O
infection	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
or	O
continuous	B-cell_line
T-leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
evaluated	O
.	O

HIVs	O
in	O
which	O
the	O
NF-kappa	B-DNA
B/Sp1	I-DNA
enhancer	I-DNA
plus	O
the	O
downstream	B-DNA
TATA	I-DNA
element	I-DNA
were	O
replaced	O
with	O
heterologous	B-DNA
enhancer/promoters	I-DNA
were	O
also	O
constructed	O
.	O

Viruses	O
containing	O
the	O
human	B-DNA
cytomegalovirus	I-DNA
immediate-early	I-DNA
enhancer	I-DNA
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild-type	O
HIV	O
in	O
activated	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
AA2	B-cell_line
cells	I-cell_line
but	O
replicated	O
less	O
efficiently	O
in	O
H9	B-cell_line
and	I-cell_line
CEM	I-cell_line
cells	I-cell_line
.	O

These	O
studies	O
indicate	O
that	O
heterologous	B-DNA
enhancer	I-DNA
elements	I-DNA
are	O
capable	O
of	O
restoring	O
Tat	B-protein
responsiveness	O
to	O
the	O
HIV	B-DNA
LTR	I-DNA
in	O
the	O
context	O
of	O
directing	O
reporter	B-DNA
gene	I-DNA
expression	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
infectious	O
progeny	O
virions	O
.	O

JoURNAL	NULL
OF	NULL
VirOLOGY	NULL
,	NULL
Feb.	NULL
1993	NULL
,	NULL
p.	NULL
743-752	NULL
0022-538	NULL
X/93/030743-10	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1993	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

67	NULL
,	NULL
No	NULL
.	NULL

3	NULL
Human	NULL
Immunodeficiency	NULL
Viruses	NULL
Containing	NULL
Heterologous	NULL
Enhancer/Promoters	NULL
Are	NULL
Replication	NULL
Competent	NULL
and	NULL
Exhibit	NULL
Different	NULL
Lymphocyte	NULL
Tropisms	NULL
LUNG-JI	NULL
CHANG	NULL
,	NULL
*	NULL
EDWARD	NULL
McNULTY	NULL
,	NULL
anp	NULL
MALCOLM	NULL
MARTIN	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Microbiology	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
Received	NULL
24	NULL
August	NULL
1992/Accepted	NULL
28	NULL
October	NULL
1992	NULL
The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-xB	NULL
)	NULL
and	NULL
the	NULL
constitutively	NULL
expressed	NULL
transcription	NULL
factor	NULL
Sp1	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
highly	NULL
conserved	NULL
in	NULL
HIV	NULL
and	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
isolates	NULL
.	NULL

To	NULL
delineate	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
motifs	NULL
on	NULL
the	NULL
replicative	NULL
capacity	NULL
of	NULL
HIV	NULL
and	NULL
to	NULL
explore	NULL
the	NULL
possibility	NULL
of	NULL
extending	NULL
the	NULL
virus	NULL
host	NULL
range	NULL
,	NULL
known	NULL
heterologous	NULL
enhancer/promoters	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
HIV-1	NULL
LTR	NULL
in	NULL
place	NULL
of	NULL
the	NULL
NF-xB	NULL
and	NULL
Sp1	NULL
binding	NULL
sites	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
these	NULL
substitutions	NULL
on	NULL
viral	NULL
replication	NULL
in	NULL
transfected	NULL
HeLa	NULL
cells	NULL
and	NULL
on	NULL
HIV	NULL
infection	NULL
of	NULL
human	NULL
peripheral	NULL
-	NULL
blood	NULL
lymphocytes	NULL
or	NULL
continuous	NULL
T-leukemia	NULL
cell	NULL
lines	NULL
were	NULL
evaluated	NULL
.	NULL

HIV	NULL
's	NULL
in	NULL
which	NULL
the	NULL
NF-xB/Sp1	NULL
enhancer	NULL
plus	NULL
the	NULL
downstream	NULL
TATA	NULL
element	NULL
were	NULL
replaced	NULL
with	NULL
heterologous	NULL
enhancer/promoters	NULL
were	NULL
also	NULL
con-structed	NULL
.	NULL

Viruses	NULL
containing	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
immediate-early	NULL
enhancer	NULL
exhibited	NULL
infectious	NULL
kinetics	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
wild-type	NULL
HIV	NULL
in	NULL
activated	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
and	NULL
AA2	NULL
cells	NULL
but	NULL
replicated	NULL
less	NULL
efficiently	NULL
in	NULL
H9	NULL
and	NULL
CEM	NULL
cells	NULL
.	NULL

These	NULL
studies	NULL
indicate	NULL
that	NULL
heterologous	NULL
enhancer	NULL
elements	NULL
are	NULL
capable	NULL
of	NULL
restoring	NULL
Tat	NULL
responsiveness	NULL
to	NULL
the	NULL
HIV	NULL
LTR	NULL
in	NULL
the	NULL
context	NULL
of	NULL
directing	NULL
reporter	NULL
gene	NULL
expression	NULL
as	NULL
well	NULL
as	NULL
in	NULL
the	NULL
production	NULL
of	NULL
infectious	NULL
progeny	NULL
virions	NULL
.	NULL

Retroviral	NULL
long	NULL
terminal	NULL
repeats	NULL
(	NULL
LTRs	NULL
)	NULL
contain	NULL
multiple	NULL
cis-acting	NULL
DNA	NULL
motifs	NULL
,	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
,	NULL
which	NULL
modulate	NULL
the	NULL
synthesis	NULL
of	NULL
viral	NULL
mRNAs	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
,	NULL
the	NULL
structures	NULL
and	NULL
functions	NULL
of	NULL
several	NULL
of	NULL
these	NULL
elements	NULL
have	NULL
been	NULL
intensively	NULL
investigated	NULL
in	NULL
the	NULL
context	NULL
of	NULL
both	NULL
LTR-directed	NULL
reporter	NULL
gene	NULL
constructs	NULL
and	NULL
full-length	NULL
proviral	NULL
DNAs	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
elements	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
Spl	NULL
and	NULL
TATA	NULL
)	NULL
bind	NULL
cellular	NULL
proteins	NULL
which	NULL
are	NULL
constitutively	NULL
expressed	NULL
in	NULL
most	NULL
eukaryotic	NULL
cells	NULL
and	NULL
influence	NULL
basal	NULL
levels	NULL
of	NULL
HIV	NULL
expression	NULL
(	NULL
19	NULL
,	NULL
30	NULL
,	NULL
31	NULL
,	NULL
40	NULL
,	NULL
43	NULL
,	NULL
44	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Others	NULL
,	NULL
such	NULL
as	NULL
the	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
and	NULL
NFAT-1	NULL
sites	NULL
,	NULL
interact	NULL
with	NULL
factors	NULL
that	NULL
are	NULL
induced	NULL
following	NULL
T-cell	NULL
activation	NULL
,	NULL
and	NULL
modulate	NULL
the	NULL
basal	NULL
levels	NULL
of	NULL
HIV	NULL
expression	NULL
(	NULL
12	NULL
,	NULL
42	NULL
,	NULL
53	NULL
,	NULL
54	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Much	NULL
of	NULL
our	NULL
knowledge	NULL
about	NULL
the	NULL
functional	NULL
properties	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
comes	NULL
from	NULL
transient	NULL
transfection	NULL
experiments	NULL
in	NULL
which	NULL
the	NULL
expression	NULL
of	NULL
LTR-driven	NULL
reporter	NULL
genes	NULL
has	NULL
been	NULL
evaluated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
virus-encoded	NULL
transactivator	NULL
Tat	NULL
(	NULL
2	NULL
,	NULL
15	NULL
,	NULL
17	NULL
,	NULL
55	NULL
)	NULL
.	NULL

In	NULL
many	NULL
instances	NULL
,	NULL
these	NULL
assays	NULL
have	NULL
been	NULL
conducted	NULL
in	NULL
epithelial	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
HeLa	NULL
or	NULL
COS	NULL
or	NULL
,	NULL
less	NULL
frequently	NULL
,	NULL
in	NULL
human	NULL
leukemic	NULL
cell	NULL
lines	NULL
(	NULL
44	NULL
,	NULL
48	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
delineating	NULL
the	NULL
role	NULL
of	NULL
cellular	NULL
factors	NULL
on	NULL
LTR-directed	NULL
expression	NULL
,	NULL
these	NULL
studies	NULL
have	NULL
also	NULL
been	NULL
useful	NULL
in	NULL
dissecting	NULL
the	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
underlying	NULL
Tat-induced	NULL
stimulation	NULL
of	NULL
viral	NULL
mRNA	NULL
synthesis	NULL
.	NULL

Unlike	NULL
prototypical	NULL
transcriptional	NULL
activators	NULL
which	NULL
interact	NULL
with	NULL
DNA	NULL
elements	NULL
situated	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
,	NULL
the	NULL
HIV-encoded	NULL
Tat	NULL
transactivator	NULL
binds	NULL
to	NULL
an	NULL
RNA	NULL
stem-bulge-loop	NULL
structure	NULL
(	NULL
designated	NULL
TAR	NULL
)	NULL
located	NULL
at	NULL
the	NULL
5	NULL
'	NULL
terminus	NULL
of	NULL
all	NULL
HIV	NULL
transcripts	NULL
(	NULL
27	NULL
,	NULL
40	NULL
,	NULL
48	NULL
)	NULL
.	NULL

This	NULL
unorthodox	NULL
transcriptional	NULL
activation	NULL
target	NULL
has	NULL
led	NULL
several	NULL
groups	NULL
to	NULL
propose	NULL
that	NULL
the	NULL
Tat	NULL
transactivator	NULL
protein	NULL
stimu-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

743	NULL
lates	NULL
viral	NULL
RNA	NULL
production	NULL
posttranscriptionally	NULL
,	NULL
perhaps	NULL
by	NULL
facilitating	NULL
the	NULL
elongation	NULL
of	NULL
nascent	NULL
mRNAs	NULL
(	NULL
16	NULL
,	NULL
33	NULL
,	NULL
36	NULL
,	NULL
38	NULL
,	NULL
51	NULL
)	NULL
.	NULL

However	NULL
,	NULL
several	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
requiring	NULL
TAR	NULL
,	NULL
the	NULL
responsiveness	NULL
of	NULL
an	NULL
HIV	NULL
LTR	NULL
to	NULL
Tat	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
upstream	NULL
enhancer	NULL
elements	NULL
(	NULL
26	NULL
,	NULL
44	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Mutations	NULL
affecting	NULL
both	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
the	NULL
Spl	NULL
elements	NULL
eliminate	NULL
the	NULL
Tat	NULL
responsiveness	NULL
of	NULL
LTR-chloram-phenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
constructs	NULL
(	NULL
4	NULL
,	NULL
37	NULL
,	NULL
44	NULL
)	NULL
and	NULL
render	NULL
a	NULL
cloned	NULL
full-length	NULL
proviral	NULL
DNA	NULL
replication	NULL
incompetent	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Replacement	NULL
of	NULL
individual	NULL
enhancer	NULL
elements	NULL
or	NULL
combinations	NULL
of	NULL
enhancer	NULL
elements	NULL
restores	NULL
biological	NULL
function	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
several	NULL
recent	NULL
studies	NULL
,	NULL
employing	NULL
Tat	NULL
fusion	NULL
proteins	NULL
,	NULL
have	NULL
demonstrated	NULL
that	NULL
Tat	NULL
can	NULL
trans-activate	NULL
the	NULL
HIV-1	NULL
promoter	NULL
by	NULL
binding	NULL
to	NULL
DNA	NULL
elements	NULL
(	NULL
4	NULL
,	NULL
32	NULL
,	NULL
56	NULL
)	NULL
.	NULL

In	NULL
two	NULL
instances	NULL
,	NULL
the	NULL
Tat	NULL
fusion	NULL
protein	NULL
interacted	NULL
with	NULL
motifs	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
32	NULL
,	NULL
56	NULL
)	NULL
,	NULL
and	NULL
in	NULL
all	NULL
cases	NULL
,	NULL
Tat	NULL
transactivation	NULL
occurred	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TAR	NULL
(	NULL
which	NULL
had	NULL
been	NULL
deleted	NULL
from	NULL
the	NULL
reporter	NULL
construct	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
heterologous	NULL
enhancer/promoter	NULL
sequences	NULL
could	NULL
be	NULL
substituted	NULL
for	NULL
the	NULL
HIV-1	NULL
Spl	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
TATA	NULL
elements	NULL
and	NULL
direct	NULL
expression	NULL
from	NULL
the	NULL
viral	NULL
LTR	NULL
.	NULL

Although	NULL
this	NULL
study	NULL
was	NULL
begun	NULL
by	NULL
using	NULL
LTR	NULL
reporter	NULL
constructs	NULL
and	NULL
Tat	NULL
supplied	NULL
in	NULL
trans	NULL
,	NULL
we	NULL
were	NULL
most	NULL
interested	NULL
in	NULL
determining	NULL
whether	NULL
the	NULL
substituted	NULL
enhancers	NULL
could	NULL
function	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
full-length	NULL
provirus	NULL
and	NULL
the	NULL
viral	NULL
genome	NULL
.	NULL

Functional	NULL
activity	NULL
could	NULL
be	NULL
restored	NULL
to	NULL
CAT	NULL
constructs	NULL
following	NULL
the	NULL
insertion	NULL
of	NULL
certain	NULL
heterologous	NULL
enhancer	NULL
motifs	NULL
into	NULL
biologically	NULL
inactive	NULL
LTRs	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
the	NULL
principal	NULL
effect	NULL
was	NULL
a	NULL
marked	NULL
elevation	NULL
of	NULL
basal	NULL
levels	NULL
of	NULL
LTR-directed	NULL
expression	NULL
,	NULL
while	NULL
in	NULL
others	NULL
,	NULL
the	NULL
basal	NULL
CAT	NULL
activity	NULL
was	NULL
unchanged	NULL
and	NULL
increased	NULL
responsiveness	NULL
to	NULL
Tat	NULL
transactivation	NULL
was	NULL
observed	NULL
.	NULL

HIV	NULL
stocks	NULL
,	NULL
containing	NULL
the	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
immediate-early	NULL
(	NULL
IE	NULL
)	NULL
enhancer	NULL
element	NULL
substituted	NULL
for	NULL
the	NULL
NF-kB	NULL
and	NULL
Spl	NULL
motifs	NULL
,	NULL
exhibited	NULL
replication	NULL
kinetics	NULL
similar	NULL
to	NULL
744	NULL
CHANG	NULL
ET	NULL
AL	NULL
.	NULL

those	NULL
of	NULL
wild-type	NULL
HIV	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBLs	NULL
)	NULL
and	NULL
in	NULL
H9	NULL
and	NULL
AA2	NULL
cells	NULL
,	NULL
grew	NULL
slowly	NULL
in	NULL
CEM	NULL
cells	NULL
,	NULL
and	NULL
were	NULL
unable	NULL
to	NULL
infect	NULL
Molt	NULL
3	NULL
,	NULL
HL60	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
propagated	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
(	NULL
DMEM	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

The	NULL
MT4	NULL
(	NULL
25	NULL
)	NULL
,	NULL
H9	NULL
(	NULL
44	NULL
)	NULL
,	NULL
and	NULL
12D7	NULL
(	NULL
isolated	NULL
by	NULL
Guido	NULL
Poli	NULL
from	NULL
the	NULL
cloned	NULL
CEM	NULL
cell	NULL
derivative	NULL
A3.01	NULL
[	NULL
18	NULL
]	NULL
)	NULL
continuous	NULL
human	NULL
T-leukemia	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

AA2	NULL
cells	NULL
,	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
B-lymphoblastoid	NULL
line	NULL
WIL-2	NULL
(	NULL
8	NULL
)	NULL
,	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
of	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
and	NULL
propagated	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
1	NULL
%	NULL
nonessential	NULL
amino	NULL
acids	NULL
and	NULL
0.1	NULL
mM	NULL
sodium	NULL
pyruvate	NULL
.	NULL

All	NULL
other	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

Human	NULL
PBLs	NULL
from	NULL
HIV-seronegative	NULL
persons	NULL
were	NULL
stimulated	NULL
with	NULL
phytohemagglutinin	NULL
(	NULL
0.25	NULL
ug/ml	NULL
)	NULL
for	NULL
3	NULL
days	NULL
prior	NULL
to	NULL
infection	NULL
and	NULL
then	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
10	NULL
%	NULL
interleukin-2	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

Plasmid	NULL
construction	NULL
.	NULL

Plasmid	NULL
pU3-R-CAT	NULL
was	NULL
constructed	NULL
by	NULL
ligating	NULL
the	NULL
1.5-kbp	NULL
HindIII	NULL
fragment	NULL
(	NULL
mapping	NULL
between	NULL
positions	NULL
8131	NULL
and	NULL
9606	NULL
[	NULL
see	NULL
reference	NULL
41	NULL
for	NULL
the	NULL
proviral	NULL
DNA	NULL
numbering	NULL
system	NULL
]	NULL
and	NULL
designated	NULL
the	NULL
U3-R	NULL
fragment	NULL
)	NULL
of	NULL
the	NULL
full-length	NULL
pNL43	NULL
HIV	NULL
cloned	NULL
proviral	NULL
DNA	NULL
(	NULL
1	NULL
)	NULL
and	NULL
the	NULL
1.6-kbp	NULL
HindIII-BamHI	NULL
fragment	NULL
(	NULL
containing	NULL
the	NULL
CAT	NULL
gene	NULL
plus	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
polyadenylation	NULL
signal	NULL
)	NULL
of	NULL
pSV2CAT	NULL
(	NULL
21	NULL
)	NULL
to	NULL
the	NULL
HindIII-plus-BamHI-di-gested	NULL
pT7T318U	NULL
vector	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

pSVtat	NULL
contains	NULL
the	NULL
tat	NULL
gene	NULL
of	NULL
HIV5y	NULL
;	NULL
,	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Plasmid	NULL
dl	NULL
.	NULL

«	NULL
kB/Sp1-U3-R-CAT	NULL
,	NULL
in	NULL
which	NULL
the	NULL
NF-kB	NULL
and	NULL
Spl	NULL
sites	NULL
were	NULL
deleted	NULL
,	NULL
was	NULL
constructed	NULL
by	NULL
M13	NULL
mutagenesis	NULL
(	NULL
34	NULL
)	NULL
using	NULL
primer	NULL
1	NULL
(	NULL
see	NULL
below	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
an	NULL
Xbal	NULL
site	NULL
plus	NULL
sequences	NULL
adjoining	NULL
the	NULL
NF-	NULL
«	NULL
B-plus-Spl	NULL
deletion	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Heterologous	NULL
enhancers	NULL
replacing	NULL
the	NULL
HIV	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
sites	NULL
were	NULL
generated	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
amplification	NULL
from	NULL
MT-1	NULL
(	NULL
pBPV	NULL
[	NULL
Pharmacia	NULL
]	NULL
)	NULL
,	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
(	NULL
pdlA23cat	NULL
[	NULL
28	NULL
]	NULL
,	NULL
provided	NULL
by	NULL
M.	NULL
Stinski	NULL
)	NULL
,	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
(	NULL
pCMV	NULL
cat	NULL
,	NULL
provided	NULL
by	NULL
S.	NULL
Venkatesan	NULL
)	NULL
,	NULL
the	NULL
murine	NULL
leukemia	NULL
virus	NULL
(	NULL
MLV	NULL
)	NULL
LTR	NULL
(	NULL
pMuLV	NULL
[	NULL
46	NULL
]	NULL
,	NULL
provided	NULL
by	NULL
R.	NULL
Re-paske	NULL
)	NULL
,	NULL
and	NULL
the	NULL
polyomavirus	NULL
(	NULL
Py	NULL
)	NULL
enhancer	NULL
A	NULL
(	NULL
pl-R	NULL
[	NULL
29	NULL
]	NULL
)	NULL
and	NULL
were	NULL
individually	NULL
inserted	NULL
into	NULL
the	NULL
XbaI	NULL
site	NULL
of	NULL
di	NULL
.	NULL

«	NULL
kB/	NULL
Sp1-U3-R-CAT	NULL
.	NULL

The	NULL
oligonucleotide	NULL
primer	NULL
pairs	NULL
(	NULL
5	NULL
'	NULL
to	NULL
3	NULL
'	NULL
)	NULL
used	NULL
for	NULL
amplification	NULL
were	NULL
primers	NULL
2	NULL
and	NULL
3	NULL
(	NULL
MT-1	NULL
)	NULL
,	NULL
primers	NULL
4	NULL
and	NULL
5	NULL
[	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
]	NULL
,	NULL
primers	NULL
6	NULL
and	NULL
5	NULL
[	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
]	NULL
,	NULL
primers	NULL
7	NULL
and	NULL
8	NULL
(	NULL
MLV	NULL
)	NULL
,	NULL
and	NULL
primers	NULL
9	NULL
and	NULL
10	NULL
(	NULL
Py	NULL
)	NULL
.	NULL

The	NULL
amplified	NULL
fragments	NULL
were	NULL
cleaved	NULL
with	NULL
Xbal	NULL
or	NULL
Nhe	NULL
!	NULL

(	NULL
for	NULL
MLV	NULL
only	NULL
)	NULL
and	NULL
inserted	NULL
into	NULL
Xbal-digested	NULL
dl.kB/Sp1-U3-R-CAT	NULL
.	NULL

HIV	NULL
LTR-directed	NULL
CAT	NULL
constructs	NULL
containing	NULL
a	NULL
heterologous	NULL
enhancer	NULL
plus	NULL
heterologous	NULL
TATA	NULL
element	NULL
from	NULL
either	NULL
CMV	NULL
or	NULL
MLV	NULL
were	NULL
also	NULL
made	NULL
by	NULL
PCR	NULL
amplification	NULL
.	NULL

Primers	NULL
containing	NULL
CMV	NULL
sequences	NULL
(	NULL
-46	NULL
to	NULL
-1	NULL
)	NULL
(	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
is	NULL
located	NULL
at	NULL
position	NULL
+1	NULL
)	NULL
and	NULL
HIV	NULL
R-region	NULL
sequences	NULL
(	NULL
+1	NULL
to	NULL
+14	NULL
[	NULL
primer	NULL
11	NULL
]	NULL
)	NULL
or	NULL
MLV	NULL
sequences	NULL
(	NULL
-59	NULL
to	NULL
-1	NULL
)	NULL
and	NULL
HIV	NULL
R	NULL
sequences	NULL
(	NULL
+1	NULL
to	NULL
+15	NULL
{	NULL
primer	NULL
13	NULL
]	NULL
)	NULL
were	NULL
synthesized	NULL
.	NULL

These	NULL
products	NULL
were	NULL
then	NULL
used	NULL
individually	NULL
with	NULL
primer	NULL
12	NULL
(	NULL
containing	NULL
HIV-1	NULL
p17	NULL
MA	NULL
sequences	NULL
(	NULL
+402	NULL
to	NULL
+385	NULL
)	NULL
to	NULL
generate	NULL
by	NULL
PCR	NULL
the	NULL
heterologous	NULL
enhancer-plus-promoter	NULL
(	NULL
E+P	NULL
)	NULL
element	NULL
linked	NULL
directly	NULL
to	NULL
the	NULL
HIV	NULL
transcription	NULL
initiation	NULL
site	NULL
plus	NULL
downstream	NULL
HIV	NULL
sequences	NULL
.	NULL

The	NULL
amplified	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
/TATA	NULL
fragment	NULL
was	NULL
cleaved	NULL
with	NULL
Xbal	NULL
plus	NULL
HindIII	NULL
and	NULL
inserted	NULL
into	NULL
dl	NULL
.	NULL

«	NULL
B/Sp1l-U3-R-CAT	NULL
J.	NULL
ViroL	NULL
.	NULL

containing	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
,	NULL
previously	NULL
restricted	NULL
with	NULL
these	NULL
two	NULL
enzymes	NULL
.	NULL

The	NULL
MLV/TATA	NULL
amplified	NULL
product	NULL
was	NULL
cleaved	NULL
with	NULL
BssHII	NULL
plus	NULL
HindIII	NULL
and	NULL
inserted	NULL
into	NULL
dl	NULL
.	NULL

«	NULL
B/Sp1-U3-R-CAT	NULL
containing	NULL
the	NULL
MLV	NULL
enhancer	NULL
,	NULL
also	NULL
previously	NULL
digested	NULL
with	NULL
the	NULL
same	NULL
two	NULL
enzymes	NULL
.	NULL

All	NULL
of	NULL
the	NULL
heterologous	NULL
enhancer/promoter	NULL
inserts	NULL
generated	NULL
by	NULL
PCR	NULL
were	NULL
confirmed	NULL
by	NULL
DNA	NULL
sequencing	NULL
.	NULL

Cloned	NULL
HIV	NULL
proviruses	NULL
with	NULL
heterologous	NULL
enhancer/promoters	NULL
were	NULL
constructed	NULL
by	NULL
ligating	NULL
three	NULL
fragments	NULL
from	NULL
a	NULL
full-length	NULL
HIV-1	NULL
molecular	NULL
clone	NULL
(	NULL
pNL43	NULL
[	NULL
1	NULL
]	NULL
)	NULL
,	NULL
two	NULL
fragments	NULL
isolated	NULL
from	NULL
HIV	NULL
LTR-CAT	NULL
plasmids	NULL
containing	NULL
inserted	NULL
heterologous	NULL
enhancer/promoters	NULL
,	NULL
and	NULL
the	NULL
BamHI-plus-PstI-digested	NULL
pT7T318U	NULL
vector	NULL
.	NULL

The	NULL
proviral	NULL
segments	NULL
used	NULL
in	NULL
the	NULL
ligation	NULL
were	NULL
(	NULL
i	NULL
)	NULL
env-U3-R	NULL
(	NULL
BamHI-Sacl	NULL
,	NULL
nucle-otides	NULL
[	NULL
nt	NULL
]	NULL
8465	NULL
to	NULL
487	NULL
[	NULL
isolated	NULL
from	NULL
a	NULL
dl	NULL
.	NULL

«	NULL
B/Sp1-U3-R-CAT	NULL
plasmid	NULL
containing	NULL
a	NULL
replacement	NULL
enhancer/promoter	NULL
]	NULL
)	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
US-gag	NULL
[	NULL
Sacl-Sph1	NULL
,	NULL
nt	NULL
487	NULL
to	NULL
1443	NULL
[	NULL
isolated	NULL
from	NULL
pNLA3	NULL
]	NULL
)	NULL
,	NULL
(	NULL
iii	NULL
)	NULL
gag-pol-envy	NULL
[	NULL
SphI-Xhol	NULL
,	NULL
nt	NULL
1443	NULL
to	NULL
8887	NULL
[	NULL
isolated	NULL
from	NULL
pNLA3	NULL
]	NULL
)	NULL
,	NULL
(	NULL
iv	NULL
)	NULL
env-U3-R	NULL
(	NULL
Xhol-HindlII	NULL
,	NULL
nt	NULL
8887	NULL
to	NULL
531	NULL
[	NULL
isolated	NULL
from	NULL
a	NULL
dl	NULL
.	NULL

«	NULL
B/Sp1l-U3-R-CAT	NULL
plasmid	NULL
with	NULL
a	NULL
replacement	NULL
enhancer/promoter	NULL
]	NULL
)	NULL
,	NULL
and	NULL
(	NULL
v	NULL
)	NULL
US-gag	NULL
(	NULL
HindIII-Pstl	NULL
,	NULL
nt	NULL
531	NULL
to	NULL
1415	NULL
[	NULL
isolated	NULL
from	NULL
pNL43	NULL
]	NULL
)	NULL
.	NULL

The	NULL
structures	NULL
of	NULL
the	NULL
reconstructed	NULL
HIV	NULL
proviral	NULL
DNAs	NULL
were	NULL
verified	NULL
by	NULL
extensive	NULL
restriction	NULL
enzyme	NULL
mapping	NULL
,	NULL
and	NULL
the	NULL
LTR	NULL
regions	NULL
were	NULL
checked	NULL
by	NULL
nucleotide	NULL
sequencing	NULL
.	NULL

Transfection	NULL
and	NULL
RNA	NULL
analysis	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
original	NULL
Ca	NULL
,	NULL
(	NULL
PO	NULL
,	NULL
)	NULL
,	NULL
-DNA	NULL
coprecipitation	NULL
procedure	NULL
(	NULL
22	NULL
)	NULL
when	NULL
they	NULL
reached	NULL
80	NULL
to	NULL
90	NULL
%	NULL
confluency	NULL
.	NULL

Six	NULL
hours	NULL
following	NULL
the	NULL
addition	NULL
of	NULL
DNA	NULL
(	NULL
0.5	NULL
ml	NULL
of	NULL
precipitated	NULL
DNA	NULL
in	NULL
5.0	NULL
ml	NULL
of	NULL
medium	NULL
)	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
20	NULL
%	NULL
glycerol	NULL
in	NULL
DMEM	NULL
(	NULL
without	NULL
serum	NULL
)	NULL
for	NULL
5	NULL
min	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
fresh	NULL
medium	NULL
,	NULL
and	NULL
then	NULL
maintained	NULL
in	NULL
DMEM	NULL
until	NULL
harvest	NULL
.	NULL

In	NULL
CAT	NULL
assays	NULL
,	NULL
the	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
3	NULL
ug	NULL
of	NULL
a	NULL
specific	NULL
CAT	NULL
plasmid	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
plasmid	NULL
pSVtat	NULL
(	NULL
0.5	NULL
ug	NULL
)	NULL
.	NULL

For	NULL
transfections	NULL
of	NULL
cloned	NULL
HIV	NULL
proviral	NULL
DNAs	NULL
,	NULL
30	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
was	NULL
added	NULL
.	NULL

The	NULL
Ca	NULL
,	NULL
(	NULL
PO	NULL
,	NULL
)	NULL
,	NULL
transfections	NULL
also	NULL
included	NULL
20	NULL
pg	NULL
of	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
as	NULL
carrier	NULL
.	NULL

AA2	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
technique	NULL
as	NULL
modified	NULL
by	NULL
Fisher	NULL
et	NULL
al	NULL
.	NULL

(	NULL
17	NULL
)	NULL
,	NULL
using	NULL
10	NULL
ug	NULL
of	NULL
CAT	NULL
plasmid	NULL
DNA	NULL
per	NULL
10	NULL
``	NULL
cells	NULL
.	NULL

Plasmid	NULL
pXGHS	NULL
(	NULL
Nichols	NULL
Institute	NULL
Diag-nostics	NULL
)	NULL
,	NULL
which	NULL
encodes	NULL
a	NULL
secreted	NULL
human	NULL
growth	NULL
hormone	NULL
that	NULL
can	NULL
be	NULL
quantitated	NULL
by	NULL
radioimmunoassay	NULL
,	NULL
was	NULL
included	NULL
(	NULL
0.5	NULL
ug	NULL
for	NULL
HeLa	NULL
cells	NULL
and	NULL
10	NULL
ug	NULL
for	NULL
AA2	NULL
cells	NULL
)	NULL
in	NULL
each	NULL
transfection	NULL
assay	NULL
.	NULL

Poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
,	NULL
prepared	NULL
from	NULL
approximately	NULL
3	NULL
x	NULL
10°	NULL
cells	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
,	NULL
was	NULL
electrophoresed	NULL
through	NULL
1.4	NULL
%	NULL
formaldehyde	NULL
agarose	NULL
gels	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
(	NULL
GeneScreen	NULL
;	NULL
DuPont	NULL
)	NULL
,	NULL
and	NULL
hybridized	NULL
to	NULL
a	NULL
full-length	NULL
HIV	NULL
proviral	NULL
genomic	NULL
probe	NULL
labeled	NULL
by	NULL
a	NULL
random-priming	NULL
reaction	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
radioactivity	NULL
on	NULL
the	NULL
membranes	NULL
was	NULL
quantitated	NULL
with	NULL
a	NULL
phosphoimager	NULL
(	NULL
Fuji	NULL
Bio-imaging	NULL
analyzer	NULL
BAS	NULL
2000	NULL
)	NULL
.	NULL

CAT	NULL
and	NULL
reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
assays	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
37	NULL
)	NULL
.	NULL

HeLa	NULL
and	NULL
AA2	NULL
cells	NULL
were	NULL
harvested	NULL
60	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
three	NULL
cycles	NULL
of	NULL
freeze-thawing	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
in	NULL
cell	NULL
lysates	NULL
was	NULL
determined	NULL
by	NULL
using	NULL
a	NULL
protein	NULL
assay	NULL
kit	NULL
from	NULL
Bio-Rad	NULL
.	NULL

To	NULL
obtain	NULL
results	NULL
within	NULL
the	NULL
linear	NULL
kinetic	NULL
range	NULL
of	NULL
CAT	NULL
activity	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
cell	NULL
lysate	NULL
used	NULL
in	NULL
each	NULL
reaction	NULL
was	NULL
adjusted	NULL
to	NULL
give	NULL
a	NULL
detectable	NULL
signal	NULL
within	NULL
1	NULL
h	NULL
and	NULL
less	NULL
than	NULL
50	NULL
%	NULL
consumption	NULL
of	NULL
the	NULL
input	NULL
substrate	NULL
[	NULL
**CJchloram-phenicol	NULL
(	NULL
0.5	NULL
Ci	NULL
;	NULL
55	NULL
mCi/mmol	NULL
;	NULL
ICN	NULL
)	NULL
.	NULL

The	NULL
enzyme	NULL
concentration	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
serial	NULL
dilution	NULL
for	NULL
lysates	NULL
with	NULL
high	NULL
levels	NULL
of	NULL
CAT	NULL
activity	NULL
.	NULL

Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
HETEROLOGOUS	NULL
ENHANCER/PROMOTER-CONTAINING	NULL
HIVs	NULL
745	NULL
TABLE	NULL
1	NULL
.	NULL

Oligonucleotide	NULL
primers	NULL
used	NULL
for	NULL
amplification	NULL
or	NULL
sequencing	NULL
Primer	NULL
Sequence	NULL
``	NULL
1	NULL
lees	NULL
ners	NULL
ees	NULL
renee	NULL
rene	NULL
senses	NULL
ea	NULL
ek	NULL
.	NULL

GCTGCTTATATGTAGCATCTAGAGACTCCGGATGCAG	NULL
2	NULL
cove	NULL
essense	NULL
esen	NULL
enne	NULL
rer	NULL
evere	NULL
eee	NULL
see	NULL
es	NULL
CCTGCAGATCTAGAAGGGGCGGTCCCGCTGTec	NULL
3	NULL
cesses	NULL
erve	NULL
esse	NULL
erv	NULL
essense	NULL
sess	NULL
essense	NULL
nees	NULL
CCAGGCCTCTTTATAGTCGTCTAGACGAGTCCGGGCGC	NULL
A	NULL
(	NULL
enne	NULL
sees	NULL
servers	NULL
eres	NULL
neenee	NULL
nese	NULL
senna	NULL
ence	NULL
.	NULL

TCTACGTATTAGTCATCTAGATTACCATGGTG	NULL
B	NULL
cles	NULL
ease	NULL
eres	NULL
recess	NULL
eres	NULL
sess	NULL
ecs	NULL
ea	NULL
GGAGCTCTGCTTATATAGACCTTCTAGAGTACACGCCTACCGCCCATTTGC	NULL
6	NULL
lesen	NULL
neenee	NULL
eens	NULL
eres	NULL
esses	NULL
eres	NULL
ense	NULL
see	NULL
eae	NULL
CATTAGTTCATAGCCTCTAGATGGAGTTCCGCG	NULL
T	NULL
core	NULL
sevens	NULL
esses	NULL
esses	NULL
sess	NULL
esen	NULL
neenee	NULL
sees	NULL
CATAACTGAGAAGCTAGCAGTTCAGATCAAGG	NULL
B	NULL
nevere	NULL
er	NULL
seee	NULL
naa	NULL
e.	NULL
CTTT	NULL
'	NULL
I	NULL
‘	NULL
ATTGAGCTCGAAGCGC	NULL
J	NULL
nese	NULL
seee	NULL
se	NULL
scene	NULL
enone	NULL
ece	NULL
nees	NULL
CTGCAGATCTAGATCAGCTTCAGAAGATGGCGG	NULL
10	NULL
2220022	NULL
serre	NULL
esse	NULL
ss	NULL
css	NULL
seee	NULL
eca	NULL
GGATGTCTAGAGGCCAGCTGCGGTCAG	NULL
LL	NULL
220	NULL
else	NULL
ees	NULL
eres	NULL
reeves	NULL
ense	NULL
sess	NULL
seee	NULL
naa	NULL
seeks	NULL
.	NULL

GTGTACTCTAGAAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGGCTCTCTCTGGTTA	NULL
12	NULL
220	NULL
ense	NULL
essere	NULL
ese	NULL
eee	NULL
rene	NULL
seen	NULL
senna	NULL
ee	NULL
.	NULL

CCCATTTATCTAATTCTCC	NULL
k	NULL
oe	NULL
CTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCACTCGGGGGTCTCTCTGGTTAG	NULL
14	NULL
2220000000000	NULL
ese	NULL
sea	NULL
esse	NULL
eee	NULL
enses	NULL
reece	NULL
ee	NULL
.	NULL

CAAGCTTTATTGAGGCTTAAGCAGTG	NULL
15	NULL
222220000	NULL
00	NULL
eee	NULL
e	NULL
esse	NULL
eee	NULL
cree	NULL
se	NULL
cera	NULL
ee	NULL
.	NULL

GCCTGCATGGAATGGATGAC	NULL
``	NULL
The	NULL
Xbal	NULL
site	NULL
is	NULL
underlined	NULL
,	NULL
and	NULL
the	NULL
Nhel	NULL
site	NULL
is	NULL
boxed	NULL
.	NULL

RT	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
49	NULL
)	NULL
,	NULL
with	NULL
the	NULL
following	NULL
modifications	NULL
.	NULL

The	NULL
supernatants	NULL
from	NULL
transfected	NULL
cells	NULL
were	NULL
spun	NULL
in	NULL
a	NULL
microcentrifuge	NULL
at	NULL
3,000	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
before	NULL
being	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
.	NULL

Supernatants	NULL
from	NULL
virus	NULL
infections	NULL
were	NULL
removed	NULL
from	NULL
cultures	NULL
after	NULL
the	NULL
cells	NULL
had	NULL
settled	NULL
.	NULL

Each	NULL
reaction	NULL
mixture	NULL
contained	NULL
10	NULL
pl	NULL
of	NULL
supernatant	NULL
and	NULL
50	NULL
pl	NULL
of	NULL
RT	NULL
cocktail	NULL
[	NULL
60	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
75	NULL
mM	NULL
KCl	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
rA	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
0.16	NULL
ug	NULL
of	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
per	NULL
ml	NULL
)	NULL
and	NULL
was	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
1	NULL
h.	NULL
The	NULL
radioactive	NULL
products	NULL
generated	NULL
in	NULL
the	NULL
CAT	NULL
and	NULL
RT	NULL
assays	NULL
were	NULL
quantitated	NULL
by	NULL
using	NULL
a	NULL
Fuji	NULL
phosphoimager	NULL
.	NULL

The	NULL
results	NULL
obtained	NULL
were	NULL
comparable	NULL
to	NULL
those	NULL
derived	NULL
by	NULL
scintillation	NULL
counting	NULL
.	NULL

HIV	NULL
infections	NULL
.	NULL

The	NULL
wild-type	NULL
and	NULL
mutant	NULL
HIV	NULL
constructs	NULL
used	NULL
in	NULL
infectivity	NULL
studies	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
supernatants	NULL
of	NULL
transfected	NULL
HeLa	NULL
cells	NULL
and	NULL
were	NULL
frozen	NULL
in	NULL
1-ml	NULL
aliquots	NULL
.	NULL

The	NULL
infections	NULL
were	NULL
initiated	NULL
by	NULL
incubating	NULL
2	NULL
x	NULL
10°	NULL
to	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
and	NULL
similar	NULL
amounts	NULL
(	NULL
as	NULL
determined	NULL
by	NULL
RT	NULL
activity	NULL
)	NULL
of	NULL
different	NULL
virus	NULL
preparations	NULL
(	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
approximately	NULL
0.002	NULL
)	NULL
in	NULL
2	NULL
ml	NULL
of	NULL
medium	NULL
at	NULL
37°C	NULL
for	NULL
3	NULL
h	NULL
with	NULL
occasional	NULL
shaking	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
,	NULL
resuspended	NULL
in	NULL
fresh	NULL
medium	NULL
,	NULL
and	NULL
split	NULL
at	NULL
a	NULL
1:3	NULL
ratio	NULL
every	NULL
3	NULL
to	NULL
4	NULL
days	NULL
.	NULL

In	NULL
the	NULL
infections	NULL
utilizing	NULL
human	NULL
PBLs	NULL
,	NULL
the	NULL
cultures	NULL
were	NULL
supplemented	NULL
with	NULL
fresh	NULL
cells	NULL
every	NULL
10	NULL
days	NULL
.	NULL

Virus	NULL
replication	NULL
was	NULL
monitored	NULL
by	NULL
RT	NULL
assay	NULL
of	NULL
the	NULL
supernatant	NULL
medium	NULL
.	NULL

RT-PCR	NULL
and	NULL
DNA	NULL
sequencing	NULL
of	NULL
the	NULL
reconstructed	NULL
HIV	NULL
LTRs	NULL
.	NULL

Cell-free	NULL
particles	NULL
,	NULL
present	NULL
in	NULL
the	NULL
supernatants	NULL
of	NULL
cells	NULL
infected	NULL
with	NULL
HIV	NULL
containing	NULL
reconstructed	NULL
LTRs	NULL
,	NULL
were	NULL
harvested	NULL
(	NULL
100	NULL
wl	NULL
)	NULL
,	NULL
centrifuged	NULL
at	NULL
top	NULL
speed	NULL
for	NULL
5	NULL
min	NULL
in	NULL
a	NULL
microcentrifuge	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
filtered	NULL
through	NULL
a	NULL
0.45-pm-pore-size	NULL
Eppendorf	NULL
spin	NULL
filter	NULL
.	NULL

The	NULL
HIV	NULL
present	NULL
in	NULL
the	NULL
filtrate	NULL
was	NULL
dissociated	NULL
by	NULL
vortexing	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
8	NULL
M	NULL
LiCl	NULL
,	NULL
placed	NULL
on	NULL
dry	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
,	NULL
transferred	NULL
to	NULL
a	NULL
-20°C	NULL
freezer	NULL
for	NULL
at	NULL
least	NULL
2	NULL
h	NULL
,	NULL
and	NULL
centrifuged	NULL
at	NULL
top	NULL
speed	NULL
in	NULL
a	NULL
microcentrifuge	NULL
at	NULL
4°C	NULL
for	NULL
20	NULL
min	NULL
.	NULL

The	NULL
RNA	NULL
pellet	NULL
was	NULL
then	NULL
rinsed	NULL
with	NULL
70	NULL
%	NULL
ethanol	NULL
,	NULL
dried	NULL
briefly	NULL
under	NULL
vacuum	NULL
,	NULL
resuspended	NULL
in	NULL
water	NULL
,	NULL
and	NULL
reverse	NULL
transcribed	NULL
by	NULL
using	NULL
the	NULL
3	NULL
'	NULL
LTR	NULL
primer	NULL
(	NULL
primer	NULL
14	NULL
,	NULL
nt	NULL
9611	NULL
to	NULL
9585	NULL
)	NULL
and	NULL
the	NULL
RiboClone	NULL
cDNA	NULL
synthesis	NULL
system	NULL
(	NULL
Promega	NULL
)	NULL
for	NULL
the	NULL
synthesis	NULL
of	NULL
the	NULL
first	NULL
DNA	NULL
strand	NULL
.	NULL

A	NULL
control	NULL
reaction	NULL
excluding	NULL
the	NULL
RT	NULL
was	NULL
performed	NULL
in	NULL
parallel	NULL
.	NULL

The	NULL
cDNA	NULL
was	NULL
amplified	NULL
by	NULL
PCR	NULL
,	NULL
using	NULL
polymerase	NULL
and	NULL
reagents	NULL
obtained	NULL
from	NULL
Perkin-Elmer	NULL
Cetus	NULL
;	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
LTR	NULL
primers	NULL
(	NULL
primers	NULL
15	NULL
and	NULL
14	NULL
,	NULL
respectively	NULL
;	NULL
0.1	NULL
mM	NULL
each	NULL
)	NULL
were	NULL
added	NULL
to	NULL
a	NULL
reaction	NULL
mixture	NULL
containing	NULL
the	NULL
cDNA	NULL
(	NULL
1/20	NULL
of	NULL
the	NULL
RT	NULL
product	NULL
)	NULL
and	NULL
amplified	NULL
for	NULL
30	NULL
cycles	NULL
under	NULL
the	NULL
following	NULL
conditions	NULL
:	NULL
94°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
58°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
3	NULL
min	NULL
.	NULL

The	NULL
product	NULL
obtained	NULL
was	NULL
then	NULL
subjected	NULL
to	NULL
asymmetric	NULL
PCR	NULL
amplification	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
two	NULL
primers	NULL
at	NULL
a	NULL
10:1	NULL
molar	NULL
ratio	NULL
)	NULL
to	NULL
generate	NULL
single-stranded	NULL
DNA	NULL
for	NULL
sequencing	NULL
as	NULL
described	NULL
by	NULL
Meltzer	NULL
et	NULL
al	NULL
.	NULL

(	NULL
39	NULL
)	NULL
.	NULL

Excess	NULL
primers	NULL
were	NULL
removed	NULL
with	NULL
a	NULL
Centricon	NULL
100	NULL
filtration	NULL
device	NULL
(	NULL
Amicon	NULL
)	NULL
after	NULL
each	NULL
amplification	NULL
step	NULL
.	NULL

Nucleotide	NULL
sequencing	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
Sequenase	NULL
and	NULL
protocols	NULL
supplied	NULL
by	NULL
U.S.	NULL
Biochemical	NULL
Corp.	NULL
Sequences	NULL
of	NULL
primers	NULL
used	NULL
for	NULL
amplication	NULL
or	NULL
sequencing	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

RESULTS	NULL
Insertion	NULL
of	NULL
heterologous	NULL
enhancer	NULL
elements	NULL
into	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Previously	NULL
published	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
mutagenesis	NULL
of	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
plus	NULL
the	NULL
three	NULL
Spl	NULL
sites	NULL
renders	NULL
HIV-1	NULL
LTR-directed	NULL
CAT	NULL
expression	NULL
unresponsive	NULL
to	NULL
Tat	NULL
(	NULL
4	NULL
,	NULL
37	NULL
,	NULL
44	NULL
)	NULL
and	NULL
renders	NULL
the	NULL
full-length	NULL
proviral	NULL
DNA	NULL
replication	NULL
incompetent	NULL
(	NULL
37	NULL
)	NULL
.	NULL

A	NULL
91-bp	NULL
segment	NULL
,	NULL
which	NULL
included	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
three	NULL
Spl	NULL
sites	NULL
,	NULL
was	NULL
deleted	NULL
from	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
an	NULL
HIV-1	NULL
LTR-CAT	NULL
construct	NULL
,	NULL
using	NULL
M13	NULL
mutagenesis	NULL
,	NULL
and	NULL
replaced	NULL
with	NULL
an	NULL
Xbal	NULL
cleavage	NULL
site	NULL
to	NULL
permit	NULL
the	NULL
subsequent	NULL
introduction	NULL
of	NULL
heterologous	NULL
enhancer	NULL
elements	NULL
approximately	NULL
90	NULL
nt	NULL
upstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
5	NULL
border	NULL
of	NULL
the	NULL
deletion	NULL
in	NULL
this	NULL
mutated	NULL
HIV	NULL
LTR	NULL
(	NULL
designated	NULL
dl	NULL
.	NULL

«	NULL
kB/Spl	NULL
)	NULL
is	NULL
actually	NULL
located	NULL
24	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
5'-most	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
,	NULL
extending	NULL
into	NULL
a	NULL
region	NULL
of	NULL
the	NULL
LTR	NULL
which	NULL
shares	NULL
nucleotide	NULL
sequence	NULL
homology	NULL
with	NULL
a	NULL
regulatory	NULL
motif	NULL
associated	NULL
with	NULL
the	NULL
T-cell	NULL
receptor	NULL
alpha	NULL
gene	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Because	NULL
a	NULL
goal	NULL
of	NULL
these	NULL
studies	NULL
was	NULL
to	NULL
insert	NULL
heterologous	NULL
promoter/enhancer	NULL
sequences	NULL
into	NULL
similarly	NULL
deleted	NULL
LTRs	NULL
associated	NULL
with	NULL
full-length	NULL
HIV	NULL
proviruses	NULL
,	NULL
care	NULL
was	NULL
taken	NULL
to	NULL
select	NULL
functional	NULL
heterologous	NULL
enhancer	NULL
elements	NULL
that	NULL
would	NULL
minimally	NULL
affect	NULL
LTR	NULL
size	NULL
or	NULL
structure	NULL
or	NULL
would	NULL
be	NULL
unlikely	NULL
to	NULL
perturb	NULL
the	NULL
subsequent	NULL
packaging	NULL
of	NULL
the	NULL
altered	NULL
viral	NULL
genome	NULL
into	NULL
progeny	NULL
particles	NULL
.	NULL

The	NULL
heterologous	NULL
enhancer	NULL
elements	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
ranging	NULL
in	NULL
size	NULL
from	NULL
111	NULL
to	NULL
326	NULL
bp	NULL
,	NULL
were	NULL
synthesized	NULL
by	NULL
PCR	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Each	NULL
element	NULL
terminated	NULL
10	NULL
bp	NULL
upstream	NULL
of	NULL
its	NULL
associated	NULL
TATA	NULL
box	NULL
except	NULL
for	NULL
the	NULL
Py	NULL
enhancer	NULL
(	NULL
7	NULL
)	NULL
,	NULL
which	NULL
is	NULL
not	NULL
situated	NULL
adjacent	NULL
to	NULL
a	NULL
TATA	NULL
element	NULL
.	NULL

The	NULL
two	NULL
CMV-IE	NULL
elements	NULL
,	NULL
designated	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
and	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
,	NULL
overlap	NULL
one	NULL
another	NULL
at	NULL
their	NULL
3	NULL
'	NULL
termini	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
;	NULL
each	NULL
has	NULL
been	NULL
J	NULL
.	NULL

Vigor	NULL
.	NULL

CHANG	NULL
ET	NULL
AL	NULL
.	NULL

746	NULL
*siInsoy	NULL
U	NULL
;	NULL
pue	NULL
spoyjoji	NULL
pue	NULL
ut	NULL
paguiosap	NULL
are	NULL
Jay	NULL
;	NULL
Jo	NULL
s	NULL
[	NULL
Itlap	NULL
oy	NULL
}	NULL
;	NULL
pue	NULL
rojowoid/reoueyuo	NULL
ay	NULL
)	NULL
Jo	NULL
ssomos	NULL
aJ	NULL
,	NULL
'uopajop	NULL
``	NULL
Jp	NULL
'	NULL
(	NULL
SE	NULL
'gZ	NULL
9	NULL
)	NULL
sjuawoja	NULL
ssoueyuo	NULL
Apo	NULL
Jo	NULL
soouanbas	NULL
jeadai	NULL
(	NULL
tz	NULL
pue	NULL
'gt	NULL
(	NULL
gt	NULL
'	NULL
(	NULL
ured	NULL
pouaaut	NULL
ue	NULL
)	NULL
sjuawojo	NULL
Jooueyua	NULL
snutaouape	NULL
'py	NULL
JFeadar	NULL
jooiip	NULL
``	NULL
yq	NULL
'juowajo	NULL
aaisuodsar-jejau	NULL
'gyJA	NULL
*saxoq	NULL
oo	NULL
ajeudisop	NULL
speaymoure	NULL
jfeuonoaitpiq	NULL
ay	NULL
)	NULL
pue	NULL
'smornre	NULL
Aq	NULL
pareaiput	NULL
10	NULL
paxoq	NULL
ore	NULL
s1019e	NULL
;	NULL
uonduosue	NULL
;	NULL
]	NULL
ay	NULL
)	NULL
103	NULL
sous	NULL
Suipurq	NULL
aandunsaid	NULL
ayy	NULL
,	NULL
aus	NULL
jeuonduosuen	NULL
ay	NULL
sajeudisap	NULL
14+	NULL
'poreoiput	NULL
are	NULL
surasut	NULL
1ojoword/rdoueyus	NULL
ou	NULL
}	NULL
se	NULL
[	NULL
Jom	NULL
se	NULL
squaurdja	NULL
VIVIL	NULL
pue	NULL
``	NULL
tds	NULL
'	NULL
g	NULL
>	NULL
-4N	NULL
T-AIH	NULL
porojop	NULL
41	NULL
30	NULL
suonisod	NULL
dew	NULL
ay	NULL
}	NULL
,	NULL
``	NULL
YLT	NULL
T-AIH	NULL
®	NULL
our	NULL
pauosut	NULL
srajowoid/rooueyua	NULL
snodojora13y	NULL
ay	NULL
)	NULL
JO	NULL
uvonejuasaidais	NULL
onewau	NULL
>	NULL
§	NULL
'	NULL
I	NULL
'Old	NULL
if	NULL
{	NULL
y	NULL
sequeyue	NULL
)	NULL
ewokjod	NULL
esnopy	NULL
]	NULL
1E18	NULL
Lzog	NULL
Law	NULL
Aeuc	NULL
;	NULL
opy	NULL
]	NULL
___	NULL
|	NULL
is	NULL
L2	NULL
7T	NULL
-r	NULL
gr	NULL
3°	NULL
Jar	NULL
.	NULL

Kqaramo	NULL
usuny	NULL
)	NULL
Eg	NULL
)	NULL
Taye	NULL
[	NULL
Am	NULL
Aeucjopy	NULL
]	NULL
|	NULL
4	NULL
>	NULL
--	NULL
--	NULL
P-P-P	NULL
--	NULL
--	NULL
|	NULL
-	NULL
#	NULL
tolarano	NULL
ueung	NULL
)	NULL
it-	NULL
``	NULL
dA	NULL
0	NULL
``	NULL
WO	NULL
``	NULL
H	NULL
C3	NULL
6t	NULL
if	NULL
0	NULL
sto	NULL
pyas	NULL
]	NULL
“	NULL
2.481	NULL
-ma	NULL
#	NULL
1	NULL
61	NULL
#	NULL
1	NULL
Ke	NULL
)	NULL
ar-And	NULL
usuny	NULL
)	NULL
TTEIIAIvI—	NULL
[	NULL
1-1	NULL
eenopy	NULL
)	NULL
--	NULL
-	NULL
--	NULL
-	NULL
$	NULL
HMIPUIH	NULL
VLVL	NULL
ldg	NULL
_	NULL
8	NULL
#	NULL
4N	NULL
|	NULL
|	NULL
_	NULL
|	NULL
|	NULL
sn	NULL
u	NULL
€	NULL
en	NULL
S17	NULL
F-AM	NULL
621	NULL
J	NULL
I	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
HETEROLOGOUS	NULL
ENHANCER/PROMOTER-CONTAINING	NULL
HIVs	NULL
747	NULL
TABLE	NULL
2	NULL
.	NULL

Relative	NULL
CAT	NULL
activities	NULL
of	NULL
HIV	NULL
U3-R-CAT	NULL
constructs	NULL
in	NULL
HeLa	NULL
and	NULL
AA2	NULL
cells	NULL
CAT	NULL
activity	NULL
``	NULL
lol	NULL
.	NULL

LTR-CAT	NULL
construct	NULL
Enhmﬁg/é	NULL
’	NULL
fmme	NULL
'	NULL
ig	NULL
rown	NULL
Transactivation	NULL
(	NULL
fold	NULL
)	NULL
HeLa	NULL
AA2	NULL
HeLa	NULL
AA2	NULL
HeLa	NULL
AA2	NULL
U3-R-CAT	NULL
(	NULL
wild	NULL
type	NULL
)	NULL
1.0	NULL
0.6	NULL
485.0	NULL
25.0	NULL
485	NULL
42	NULL
dl	NULL
.	NULL

«	NULL
B/Sp1l	NULL
None	NULL
_P	NULL
-	NULL
-	NULL
0.4	NULL
_-	NULL
__	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
182.0	NULL
2.0	NULL
995.5	NULL
19.5	NULL
6	NULL
10	NULL
CVM-IE	NULL
(	NULL
a	NULL
)	NULL
(	NULL
inverted	NULL
)	NULL
17.0	NULL
ND	NULL
233.0	NULL
ND	NULL
14	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
13.5	NULL
2.0	NULL
281.0	NULL
27.5	NULL
21	NULL
14	NULL
MT-I	NULL
0.9	NULL
-	NULL
2.0	NULL
0.5	NULL
2	NULL
MLV	NULL
0.6	NULL
-	NULL
38.0	NULL
0.7	NULL
63	NULL
Py	NULL
0.7	NULL
-	NULL
62.5	NULL
3.0	NULL
89	NULL
dl	NULL
.	NULL

«	NULL
kB/Spl/TATA	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
/TATA	NULL
88.0	NULL
2.0	NULL
372.0	NULL
15.5	NULL
4	NULL
8	NULL
MLV/TATA	NULL
0.4	NULL
0.3	NULL
67.5	NULL
1.0	NULL
168	NULL
3	NULL
``	NULL
Relative	NULL
to	NULL
the	NULL
CAT	NULL
activity	NULL
of	NULL
uninduced	NULL
U3-R-CAT	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
arbitrarily	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
1.0	NULL
.	NULL

The	NULL
CAT	NULL
activities	NULL
represent	NULL
reproducible	NULL
mean	NULL
values	NULL
from	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
and	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
growth	NULL
hormone	NULL
plasmid	NULL
construct	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

®	NULL
-	NULL
,	NULL
undetectable	NULL
.	NULL

©	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

shown	NULL
to	NULL
be	NULL
as	NULL
active	NULL
as	NULL
the	NULL
full-length	NULL
CMV-IE	NULL
enhancer	NULL
{	NULL
(	NULL
~500	NULL
bp	NULL
)	NULL
in	NULL
human	NULL
epithelial	NULL
cell	NULL
lines	NULL
and	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
28	NULL
)	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
the	NULL
five	NULL
heterologous	NULL
enhancer	NULL
sequences	NULL
were	NULL
inserted	NULL
into	NULL
dl	NULL
.	NULL

«	NULL
B/Sp1	NULL
LTR	NULL
10	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
HIV	NULL
TATA	NULL
element	NULL
.	NULL

Another	NULL
mutated	NULL
LTR	NULL
(	NULL
dl	NULL
.	NULL

«	NULL
B/Spl/TATA	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
was	NULL
constructed	NULL
to	NULL
evaluate	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
heterologous	NULL
enhancer	NULL
plus	NULL
its	NULL
associated	NULL
TATA	NULL
motif	NULL
,	NULL
functioning	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
.	NULL

This	NULL
recipient	NULL
dl	NULL
.	NULL

«	NULL
B/Spl/TATA	NULL
LTR	NULL
contained	NULL
a	NULL
129-bp	NULL
deletion	NULL
encompassing	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
elements	NULL
,	NULL
the	NULL
HIV-1	NULL
TATA	NULL
box	NULL
,	NULL
and	NULL
downstream	NULL
sequences	NULL
extending	NULL
to	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
the	NULL
266-bp	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
/TATA	NULL
and	NULL
367-bp	NULL
MLV	NULL
enhancer/TATA	NULL
segments	NULL
were	NULL
inserted	NULL
into	NULL
dl	NULL
.	NULL

«	NULL
B/	NULL
Spl/TATA	NULL
so	NULL
that	NULL
transcription	NULL
would	NULL
be	NULL
initiated	NULL
near	NULL
the	NULL
authentic	NULL
HIV-1	NULL
start	NULL
site	NULL
.	NULL

The	NULL
structures	NULL
of	NULL
all	NULL
seven	NULL
reconstructed	NULL
HIV	NULL
LTRs	NULL
were	NULL
confirmed	NULL
by	NULL
nucleotide	NULL
sequencing	NULL
.	NULL

Tat	NULL
responsiveness	NULL
of	NULL
reconstructed	NULL
HIV	NULL
LTRs	NULL
containing	NULL
heterologous	NULL
enhancer	NULL
elements	NULL
.	NULL

As	NULL
a	NULL
first	NULL
step	NULL
in	NULL
assessing	NULL
whether	NULL
the	NULL
heterologous	NULL
enhancers	NULL
or	NULL
heterologous	NULL
E+P	NULL
elements	NULL
would	NULL
restore	NULL
function	NULL
,	NULL
CAT	NULL
expression	NULL
,	NULL
directed	NULL
by	NULL
wild-type	NULL
and	NULL
reconstructed	NULL
LTRs	NULL
,	NULL
was	NULL
monitored	NULL
60	NULL
h	NULL
following	NULL
transfection	NULL
of	NULL
HeLa	NULL
or	NULL
AA2	NULL
cells	NULL
(	NULL
a	NULL
CD4*	NULL
human	NULL
B-lymphocyte	NULL
cell	NULL
line	NULL
[	NULL
8	NULL
]	NULL
)	NULL
.	NULL

Tat	NULL
transactivated	NULL
the	NULL
wild-type	NULL
HIV	NULL
LTR	NULL
approximately	NULL
500-	NULL
and	NULL
40-fold	NULL
in	NULL
HeLa	NULL
and	NULL
AA2	NULL
cells	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
;	NULL
no	NULL
Tat	NULL
transactivation	NULL
of	NULL
the	NULL
enhancerless	NULL
dl.kB/Spl	NULL
LTR	NULL
vector	NULL
was	NULL
detected	NULL
in	NULL
either	NULL
cell	NULL
type	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
2	NULL
,	NULL
both	NULL
of	NULL
the	NULL
CMV	NULL
enhancer	NULL
elements	NULL
substantially	NULL
increased	NULL
the	NULL
basal	NULL
levels	NULL
of	NULL
CAT	NULL
expression	NULL
directed	NULL
by	NULL
the	NULL
dl	NULL
.	NULL

«	NULL
B/Spl	NULL
LTR	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

Although	NULL
only	NULL
a	NULL
sixfold	NULL
Tat	NULL
response	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
construct	NULL
containing	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
,	NULL
the	NULL
final	NULL
level	NULL
of	NULL
CAT	NULL
activity	NULL
was	NULL
nearly	NULL
twice	NULL
(	NULL
995	NULL
versus	NULL
485	NULL
)	NULL
that	NULL
directed	NULL
by	NULL
the	NULL
wild-type	NULL
LTR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
.	NULL

Interestingly	NULL
,	NULL
approximately	NULL
50-	NULL
and	NULL
100-fold	NULL
Tat	NULL
transactivation	NULL
was	NULL
observed	NULL
in	NULL
HeLa	NULL
cells	NULL
when	NULL
the	NULL
MLV	NULL
or	NULL
the	NULL
Py	NULL
enhancer	NULL
,	NULL
respectively	NULL
,	NULL
was	NULL
present	NULL
in	NULL
di	NULL
.	NULL

«	NULL
B/Spl	NULL
.	NULL

In	NULL
AA2	NULL
cells	NULL
,	NULL
Tat	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
containing	NULL
heterologous	NULL
enhancers	NULL
was	NULL
marginal	NULL
at	NULL
best	NULL
and	NULL
was	NULL
observed	NULL
only	NULL
with	NULL
the	NULL
two	NULL
CMV	NULL
enhancer	NULL
replacements	NULL
.	NULL

The	NULL
HIV	NULL
LTR	NULL
with	NULL
a	NULL
replacement	NULL
metallothionein	NULL
enhancer	NULL
failed	NULL
to	NULL
respond	NULL
to	NULL
Tat	NULL
in	NULL
both	NULL
cell	NULL
types	NULL
.	NULL

Heterologous	NULL
E+P	NULL
elements	NULL
were	NULL
also	NULL
introduced	NULL
into	NULL
the	NULL
HIV	NULL
LTR	NULL
to	NULL
ascertain	NULL
whether	NULL
the	NULL
TATA	NULL
box	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
Spl	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
elements	NULL
,	NULL
could	NULL
be	NULL
replaced	NULL
without	NULL
abolishing	NULL
responsiveness	NULL
to	NULL
Tat	NULL
.	NULL

The	NULL
insertion	NULL
of	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
E+P	NULL
module	NULL
significantly	NULL
increased	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
CAT	NULL
;	NULL
although	NULL
its	NULL
response	NULL
to	NULL
Tat	NULL
was	NULL
only	NULL
fourfold	NULL
,	NULL
CAT	NULL
expression	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
was	NULL
nearly	NULL
80	NULL
%	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
LTR	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
HIV	NULL
LTR	NULL
containing	NULL
a	NULL
replacement	NULL
MLV	NULL
E+P	NULL
module	NULL
directed	NULL
low	NULL
basal	NULL
levels	NULL
of	NULL
expression	NULL
which	NULL
could	NULL
be	NULL
transactivated	NULL
approximately	NULL
170-fold	NULL
by	NULL
Tat	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

The	NULL
latter	NULL
construct	NULL
,	NULL
however	NULL
,	NULL
had	NULL
little	NULL
if	NULL
any	NULL
activity	NULL
in	NULL
the	NULL
human	NULL
B-cell	NULL
line	NULL
AA2	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
relatively	NULL
long	NULL
half-life	NULL
of	NULL
CAT	NULL
protein	NULL
,	NULL
the	NULL
measurement	NULL
of	NULL
CAT	NULL
activity	NULL
may	NULL
not	NULL
accurately	NULL
reflect	NULL
HIV	NULL
LTR-directed	NULL
RNA	NULL
production	NULL
(	NULL
47	NULL
)	NULL
,	NULL
particularly	NULL
in	NULL
experiments	NULL
such	NULL
as	NULL
these	NULL
in	NULL
which	NULL
heterologous	NULL
enhancer/	NULL
promoter	NULL
elements	NULL
are	NULL
being	NULL
evaluated	NULL
.	NULL

Consequently	NULL
,	NULL
Northern	NULL
(	NULL
RNA	NULL
)	NULL
blot	NULL
hybridization	NULL
(	NULL
with	NULL
subsequent	NULL
quantitation	NULL
by	NULL
using	NULL
a	NULL
phosphoimager	NULL
)	NULL
was	NULL
used	NULL
to	NULL
monitor	NULL
the	NULL
synthesis	NULL
of	NULL
CAT	NULL
RNA	NULL
in	NULL
HeLa	NULL
cells	NULL
directed	NULL
by	NULL
the	NULL
wild-type	NULL
HIV	NULL
LTR	NULL
or	NULL
the	NULL
seven	NULL
reconstructed	NULL
LTRs	NULL
containing	NULL
replacement	NULL
enhancer	NULL
or	NULL
E+P	NULL
modules	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
3	NULL
,	NULL
several	NULL
of	NULL
the	NULL
constructs	NULL
expressed	NULL
substantial	NULL
levels	NULL
of	NULL
RNA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
dl	NULL
.	NULL

«	NULL
B/Spl	NULL
LTR	NULL
containing	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
,	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
CAT	NULL
RNA	NULL
production	NULL
was	NULL
12-fold	NULL
higher	NULL
than	NULL
the	NULL
wild-type	NULL
levels	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
insertion	NULL
of	NULL
the	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
enhancer	NULL
led	NULL
to	NULL
only	NULL
a	NULL
marginal	NULL
elevation	NULL
of	NULL
basal	NULL
RNA	NULL
synthesis	NULL
and	NULL
an	NULL
additional	NULL
17-fold	NULL
increase	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
.	NULL

The	NULL
transcriptional	NULL
start	NULL
sites	NULL
of	NULL
RNAs	NULL
expressed	NULL
from	NULL
the	NULL
LTR	NULL
chimeric	NULL
constructs	NULL
containing	NULL
the	NULL
CMV	NULL
enhancer	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
located	NULL
at	NULL
the	NULL
authentic	NULL
initiation	NULL
site	NULL
by	NULL
an	NULL
RNase	NULL
mapping	NULL
experiment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
LTR	NULL
containing	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
E+P	NULL
module	NULL
initiated	NULL
transcription	NULL
at	NULL
position	NULL
-1	NULL
(	NULL
also	NULL
a	NULL
G	NULL
residue	NULL
)	NULL
;	NULL
the	NULL
LTR	NULL
containing	NULL
the	NULL
MLV	NULL
E+P	NULL
module	NULL
initiated	NULL
transcription	NULL
at	NULL
position	NULL
-2	NULL
(	NULL
also	NULL
a	NULL
G	NULL
residue	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Replicative	NULL
properties	NULL
of	NULL
HIV	NULL
proviral	NULL
DNAs	NULL
with	NULL
reconstructed	NULL
LTRs	NULL
containing	NULL
heterologous	NULL
enhancers	NULL
or	NULL
E+P	NULL
elements	NULL
.	NULL

A	NULL
more	NULL
physiologically	NULL
relevant	NULL
assessment	NULL
of	NULL
the	NULL
reconstructed	NULL
HIV	NULL
LTRs	NULL
would	NULL
be	NULL
an	NULL
examination	NULL
of	NULL
their	NULL
functional	NULL
properties	NULL
as	NULL
regulatory	NULL
components	NULL
of	NULL
cloned	NULL
proviral	NULL
DNAs	NULL
.	NULL

This	NULL
was	NULL
evaluated	NULL
by	NULL
first	NULL
transferring	NULL
the	NULL
equivalent	NULL
of	NULL
the	NULL
dl	NULL
.	NULL

«	NULL
B/Spl	NULL
or	NULL
the	NULL
dl	NULL
.	NULL

«	NULL
B/Sp1l/TATA	NULL
LTR	NULL
748	NULL
CHANG	NULL
ET	NULL
AL	NULL
.	NULL

TABLE	NULL
3	NULL
.	NULL

Relative	NULL
RNA	NULL
expression	NULL
of	NULL
HIV	NULL
U3-R-CAT	NULL
constructs	NULL
in	NULL
HeLa	NULL
cells	NULL
J.	NULL
Viror	NULL
.	NULL

TABLE	NULL
4	NULL
.	NULL

Relative	NULL
levels	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
viral	NULL
RNA	NULL
and	NULL
RT	NULL
activity	NULL
of	NULL
HIV-1	NULL
proviral	NULL
mutants	NULL
expressed	NULL
in	NULL
HeLa	NULL
cells	NULL
LTR-CAT	NULL
Enhancer/promoter	NULL
RNA	NULL
level	NULL
``	NULL
agxzﬁin	NULL
construct	NULL
insert	NULL
-Tat	NULL
+Tat	NULL
_	NULL
(	NULL
fold	NULL
)	NULL
U3-R-CAT	NULL
1	NULL
34	NULL
34	NULL
{	NULL
wild	NULL
type	NULL
)	NULL
dl	NULL
.	NULL

«	NULL
B/Spl	NULL
None	NULL
_8	NULL
__	NULL
ND	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
12	NULL
-	NULL
61	NULL
5	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
(	NULL
inverted	NULL
)	NULL
ND	NULL
-	NULL
ND	NULL
ND	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
3	NULL
50	NULL
17	NULL
MT-I	NULL
1	NULL
1	NULL
1	NULL
MLV	NULL
2	NULL
8	NULL
4	NULL
Py	NULL
3°	NULL
»	NULL
A	NULL
7	NULL
dL	NULL
.	NULL

«	NULL
B/Spl	NULL
,	NULL
/TATA	NULL
-	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
TATA	NULL
3	NULL
0	NULL
26	NULL
9	NULL
MLV/TATA	NULL
1	NULL
3	NULL
3	NULL
*	NULL
Measured	NULL
from	NULL
radioactive	NULL
signals	NULL
on	NULL
RNA	NULL
blots	NULL
by	NULL
using	NULL
a	NULL
phosphoimager	NULL
and	NULL
normalized	NULL
by	NULL
quantitating	NULL
actin	NULL
RNA	NULL
;	NULL
values	NULL
are	NULL
relative	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
uninduced	NULL
U3-R-CAT	NULL
,	NULL
which	NULL
is	NULL
arbitrarily	NULL
assigned	NULL
a	NULL
value	NULL
of	NULL
1	NULL
.	NULL

*	NULL
-	NULL
,	NULL
undetectable	NULL
.	NULL

©	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

deletion	NULL
into	NULL
the	NULL
full-length	NULL
HIV-1	NULL
infectious	NULL
molecular	NULL
clone	NULL
pNL43	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
then	NULL
introducing	NULL
the	NULL
heterologous	NULL
enhancer	NULL
or	NULL
E+P	NULL
elements	NULL
into	NULL
the	NULL
5'-	NULL
and	NULL
3'-deleted	NULL
LTRs	NULL
of	NULL
a	NULL
full-length	NULL
proviral	NULL
DNA	NULL
clone	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
such	NULL
HIV	NULL
proviruses	NULL
was	NULL
then	NULL
monitored	NULL
by	NULL
the	NULL
production	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
viral	NULL
RNA	NULL
and	NULL
RT	NULL
activity	NULL
in	NULL
transfected	NULL
HeLa	NULL
cells	NULL
.	NULL

This	NULL
assay	NULL
measures	NULL
only	NULL
one	NULL
aspect	NULL
of	NULL
HIV	NULL
infection	NULL
cycle	NULL
:	NULL
the	NULL
synthesis	NULL
of	NULL
viral	NULL
RNA	NULL
and	NULL
progeny	NULL
virions	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
Table	NULL
4	NULL
,	NULL
the	NULL
two	NULL
CMV-IE	NULL
enhancer	NULL
elements	NULL
restored	NULL
replication	NULL
competence	NULL
to	NULL
the	NULL
HIV	NULL
provirus	NULL
in	NULL
which	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
9.2kb-	NULL
4.3kb-	NULL
2.0kb-	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

HIV	NULL
RNA	NULL
synthesis	NULL
in	NULL
transfected	NULL
HeLa	NULL
cells	NULL
.	NULL

Proviral	NULL
DNA	NULL
and	NULL
the	NULL
human	NULL
growth	NULL
hormone	NULL
plasmid	NULL
(	NULL
pXGHS	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
HeLa	NULL
cells	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Cytoplasmic	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNAs	NULL
were	NULL
purified	NULL
from	NULL
the	NULL
equivalent	NULL
of	NULL
one	NULL
half	NULL
of	NULL
a	NULL
T25	NULL
flask	NULL
and	NULL
hybridized	NULL
to	NULL
a	NULL
full-length	NULL
HIV	NULL
probe	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
endogenous	NULL
actin	NULL
RNA	NULL
present	NULL
in	NULL
each	NULL
lane	NULL
were	NULL
used	NULL
for	NULL
sample	NULL
normalization	NULL
.	NULL

WT	NULL
,	NULL
wild	NULL
type	NULL
;	NULL
inv	NULL
.	NULL

,	NULL
inverted	NULL
.	NULL

Poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
#	NULL
HIV	NULL
construct	NULL
(	NULL
%	NULL
)	NULL
RT	NULL
(	NULL
%	NULL
)	NULL
Wild	NULL
type	NULL
100	NULL
100	NULL
dl	NULL
.	NULL

«	NULL
B/Spl	NULL
2	NULL
0.003	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
50	NULL
12	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
(	NULL
inverted	NULL
)	NULL
60	NULL
13	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
110	NULL
35	NULL
MLV	NULL
2	NULL
0.003	NULL
Py	NULL
2	NULL
0.003	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
/TATA	NULL
4	NULL
0.6	NULL
MLV/TATA	NULL
2	NULL
0.3	NULL
``	NULL
Measured	NULL
from	NULL
radioactivity	NULL
on	NULL
RNA	NULL
blots	NULL
by	NULL
using	NULL
a	NULL
phosphoimager	NULL
.	NULL

Values	NULL
are	NULL
relative	NULL
to	NULL
the	NULL
wild-type	NULL
RNA	NULL
level	NULL
,	NULL
which	NULL
is	NULL
arbitrarily	NULL
given	NULL
a	NULL
value	NULL
of	NULL
100	NULL
%	NULL
.	NULL

®	NULL
Determined	NULL
at	NULL
the	NULL
time	NULL
when	NULL
samples	NULL
for	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
analysis	NULL
were	NULL
harvested	NULL
;	NULL
assayed	NULL
by	NULL
using	NULL
10	NULL
pl	NULL
of	NULL
transfected	NULL
HeLa	NULL
cell	NULL
supernatant	NULL
.	NULL

Spl	NULL
elements	NULL
had	NULL
been	NULL
deleted	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
the	NULL
quantitation	NULL
of	NULL
viral	NULL
RNA	NULL
synthesis	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
has	NULL
been	NULL
normalized	NULL
both	NULL
for	NULL
transfection	NULL
(	NULL
by	NULL
human	NULL
growth	NULL
hormone	NULL
cotransfection	NULL
)	NULL
and	NULL
for	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
harvested	NULL
(	NULL
by	NULL
probing	NULL
for	NULL
endogenous	NULL
actin	NULL
RNA	NULL
[	NULL
Fig	NULL
.	NULL

2	NULL
]	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
the	NULL
provirus	NULL
containing	NULL
MLV	NULL
and	NULL
Py	NULL
enhancer	NULL
sequences	NULL
failed	NULL
to	NULL
generate	NULL
detectable	NULL
HIV	NULL
RNA	NULL
following	NULL
transfection	NULL
,	NULL
whereas	NULL
cloned	NULL
proviral	NULL
DNA	NULL
carrying	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
in	NULL
the	NULL
inverted	NULL
orientation	NULL
directed	NULL
the	NULL
synthesis	NULL
of	NULL
substantial	NULL
amounts	NULL
of	NULL
viral	NULL
RNA	NULL
.	NULL

The	NULL
proviral	NULL
DNA	NULL
constructs	NULL
harboring	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
and	NULL
MLV	NULL
E+P	NULL
modules	NULL
(	NULL
in	NULL
place	NULL
of	NULL
the	NULL
HIV	NULL
enhancer	NULL
plus	NULL
the	NULL
HIV	NULL
TATA	NULL
motifs	NULL
)	NULL
both	NULL
failed	NULL
to	NULL
express	NULL
significant	NULL
levels	NULL
of	NULL
viral	NULL
RNA	NULL
despite	NULL
the	NULL
robust	NULL
levels	NULL
of	NULL
CAT	NULL
expression	NULL
directed	NULL
by	NULL
an	NULL
identically	NULL
reconstructed	NULL
LTR	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
sizes	NULL
of	NULL
the	NULL
three	NULL
major	NULL
species	NULL
of	NULL
viral	NULL
RNA	NULL
directed	NULL
by	NULL
LTRs	NULL
containing	NULL
the	NULL
CMV-IE	NULL
enhancers	NULL
were	NULL
each	NULL
larger	NULL
than	NULL
those	NULL
present	NULL
in	NULL
cells	NULL
transfected	NULL
by	NULL
the	NULL
wild-type	NULL
pNL43	NULL
cloned	NULL
provirus	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
reflecting	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
enlarged	NULL
U3	NULL
region	NULL
(	NULL
and	NULL
confirmed	NULL
by	NULL
sequencing	NULL
;	NULL
see	NULL
below	NULL
)	NULL
.	NULL

The	NULL
HIV	NULL
proviral	NULL
DNAs	NULL
containing	NULL
the	NULL
three	NULL
different	NULL
CMV	NULL
enhancer	NULL
elements	NULL
(	NULL
but	NULL
with	NULL
the	NULL
HIV	NULL
TATA	NULL
box	NULL
still	NULL
present	NULL
)	NULL
all	NULL
released	NULL
RT	NULL
activity	NULL
into	NULL
the	NULL
supernatant	NULL
medium	NULL
following	NULL
their	NULL
transfection	NULL
into	NULL
HeLa	NULL
cells	NULL
(	NULL
Table	NULL
4	NULL
)	NULL
.	NULL

In	NULL
all	NULL
three	NULL
cases	NULL
,	NULL
however	NULL
,	NULL
the	NULL
production	NULL
of	NULL
progeny	NULL
virions	NULL
was	NULL
lower	NULL
than	NULL
with	NULL
the	NULL
wild-type	NULL
proviral	NULL
DNA	NULL
clone	NULL
.	NULL

Infectivity	NULL
of	NULL
HIV	NULL
stocks	NULL
containing	NULL
heterologous	NULL
enhancers	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
(	NULL
in	NULL
both	NULL
orienta-tions	NULL
)	NULL
and	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
enhancer	NULL
elements	NULL
restored	NULL
HIV	NULL
replicative	NULL
capacity	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
this	NULL
type	NULL
of	NULL
assay	NULL
(	NULL
tran-sient	NULL
transfection	NULL
)	NULL
monitors	NULL
only	NULL
a	NULL
single	NULL
cycle	NULL
of	NULL
virus	NULL
growth	NULL
and	NULL
not	NULL
a	NULL
spreading	NULL
infection	NULL
of	NULL
CD4*	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
HIV	NULL
containing	NULL
heterologous	NULL
enhancers	NULL
and	NULL
E+P	NULL
elements	NULL
could	NULL
productively	NULL
infect	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
activated	NULL
human	NULL
PBLs	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
cell-free	NULL
virus	NULL
present	NULL
in	NULL
the	NULL
supernatants	NULL
of	NULL
transfected	NULL
HeLa	NULL
cells	NULL
.	NULL

In	NULL
each	NULL
instance	NULL
,	NULL
equivalent	NULL
amounts	NULL
of	NULL
HIV	NULL
,	NULL
as	NULL
determined	NULL
from	NULL
RT	NULL
activity	NULL
,	NULL
were	NULL
used	NULL
as	NULL
inocula	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
virus	NULL
containing	NULL
the	NULL
substituted	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
and	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
enhancer	NULL
elements	NULL
readily	NULL
established	NULL
a	NULL
spreading	NULL
infection	NULL
in	NULL
cultures	NULL
of	NULL
human	NULL
PBLs	NULL
.	NULL

Infectivity	NULL
was	NULL
also	NULL
observed	NULL
,	NULL
albeit	NULL
with	NULL
delayed	NULL
kinetics	NULL
,	NULL
with	NULL
virus	NULL
in	NULL
which	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
was	NULL
present	NULL
in	NULL
an	NULL
inverted	NULL
orientation	NULL
.	NULL

Since	NULL
HIV	NULL
mutants	NULL
containing	NULL
mutated	NULL
LTRs	NULL
have	NULL
previously	NULL
been	NULL
reported	NULL
to	NULL
exhibit	NULL
variable	NULL
replicative	NULL
capacities	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
HETEROLOGOUS	NULL
ENHANCER/PROMOTER-CONTAINING	NULL
HIVs	NULL
749	NULL
8000	NULL
7	NULL
dpi	NULL
:	NULL
6	NULL
9	NULL
12	NULL
15	NULL
18	NULL
21	NULL
24	NULL
27	NULL
30	NULL
33	NULL
36	NULL
39	NULL
42	NULL
45	NULL
48	NULL
--	NULL
O	NULL
--	NULL
MOCK	NULL
B	NULL
,	NULL
&	NULL
MOCK	NULL
e000	NULL
-	NULL
-e-	NULL
wt	NULL
bo	NULL
aL	NULL
A	NULL
wt	NULL
@	NULL
4	NULL
'	NULL
``	NULL
IM	NULL
``	NULL
.	NULL

F	NULL
CMV-E	NULL
(	NULL
b	NULL
)	NULL
®	NULL
©	NULL
*	NULL
,	NULL
eCo	NULL
+-	NULL
#	NULL
=	NULL
_	NULL
CMW-IE®	NULL
)	NULL
F	NULL
CMV	NULL
:	NULL
E	NULL
(	NULL
a	NULL
)	NULL
-	NULL
+eDe	NULL
-	NULL
-	NULL
*	NULL
00	NULL
0°	NULL
3	NULL
-	NULL
CMV-lE	NULL
(	NULL
a	NULL
)	NULL
(	NULL
inv	NULL
.	NULL
)	NULL

te	NULL
€	NULL
CMV-1E	NULL
(	NULL
a	NULL
)	NULL
(	NULL
inv	NULL
.	NULL
)	NULL

4	NULL
&	NULL
4000	NULL
{	NULL
A	NULL
C	NULL
IC	NULL
2000	NULL
4	NULL
dpi	NULL
:	NULL
6	NULL
9	NULL
12	NULL
15	NULL
18	NULL
21	NULL
24	NULL
27	NULL
30	NULL
33	NULL
36	NULL
39	NULL
42	NULL
45	NULL
48	NULL
MOCK	NULL
,	NULL
..	NULL
CMV-1E	NULL
(	NULL
a	NULL
)	NULL
(	NULL
inv	NULL
.	NULL
)	NULL

#	NULL
*	NULL
.	NULL
'	NULL

.	NULL

#	NULL
0	NULL
1	NULL
°	NULL
0	NULL
20	NULL
t	NULL
days	NULL
post-infection	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Infectivity	NULL
of	NULL
HIV	NULL
containing	NULL
heterologous	NULL
enhancer/promoter	NULL
elements	NULL
in	NULL
PBLs	NULL
and	NULL
H9	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
viruses	NULL
containing	NULL
the	NULL
indicated	NULL
promoter/enhancers	NULL
were	NULL
harvested	NULL
from	NULL
the	NULL
supernatants	NULL
of	NULL
transfected	NULL
HeLa	NULL
cells	NULL
(	NULL
following	NULL
normalization	NULL
for	NULL
RT	NULL
activity	NULL
[	NULL
6	NULL
x	NULL
10+	NULL
cpm	NULL
]	NULL
)	NULL
and	NULL
were	NULL
adsorbed	NULL
to	NULL
activated	NULL
PBLs	NULL
(	NULL
3	NULL
x	NULL
10°	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
3	NULL
h.	NULL
Supernatant	NULL
medium	NULL
was	NULL
collected	NULL
every	NULL
3	NULL
days	NULL
,	NULL
and	NULL
fresh	NULL
PBLs	NULL
(	NULL
3	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
added	NULL
at	NULL
7-	NULL
to	NULL
10-day	NULL
intervals	NULL
.	NULL

(	NULL
B	NULL
)	NULL
H9	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HIV	NULL
containing	NULL
CMV-IE	NULL
enhancer/promoters	NULL
as	NULL
described	NULL
for	NULL
panel	NULL
A	NULL
for	NULL
activated	NULL
PBLs	NULL
.	NULL

The	NULL
arrowhead	NULL
indicates	NULL
the	NULL
viral	NULL
progeny	NULL
that	NULL
was	NULL
sequenced	NULL
.	NULL

The	NULL
arrow	NULL
depicts	NULL
the	NULL
time	NULL
point	NULL
when	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
inverted	NULL
(	NULL
inv	NULL
.	NULL
)	NULL

virus	NULL
stock	NULL
was	NULL
harvested	NULL
and	NULL
used	NULL
as	NULL
the	NULL
inoculum	NULL
for	NULL
a	NULL
second	NULL
passage	NULL
in	NULL
H9	NULL
cells	NULL
,	NULL
shown	NULL
in	NULL
panel	NULL
C.	NULL
The	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
virus	NULL
used	NULL
in	NULL
panel	NULL
C	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
infection	NULL
of	NULL
H9	NULL
cells	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
.	NULL

d.p.i	NULL
.	NULL

,	NULL
days	NULL
postinfection	NULL
.	NULL

depending	NULL
on	NULL
the	NULL
human	NULL
T-cell	NULL
line	NULL
examined	NULL
(	NULL
37	NULL
,	NULL
49	NULL
)	NULL
,	NULL
the	NULL
infectivity	NULL
of	NULL
HIV	NULL
harboring	NULL
heterologous	NULL
enhancer	NULL
elements	NULL
was	NULL
also	NULL
evaluated	NULL
in	NULL
several	NULL
different	NULL
human	NULL
leukemia	NULL
cell	NULL
lines	NULL
.	NULL

Figure	NULL
3B	NULL
shows	NULL
virus	NULL
production	NULL
in	NULL
H9	NULL
cells	NULL
following	NULL
infection	NULL
with	NULL
three	NULL
HIV	NULL
LTR	NULL
mutants	NULL
containing	NULL
replacement	NULL
CMV	NULL
enhancer	NULL
motifs	NULL
.	NULL

The	NULL
HIV	NULL
stock	NULL
with	NULL
the	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
enhancer	NULL
exhibited	NULL
infection	NULL
kinetics	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
wild-type	NULL
virus	NULL
in	NULL
H9	NULL
cells	NULL
,	NULL
while	NULL
the	NULL
replication	NULL
of	NULL
virus	NULL
containing	NULL
the	NULL
substituted	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
was	NULL
delayed	NULL
by	NULL
approximately	NULL
10	NULL
days	NULL
.	NULL

HIV	NULL
containing	NULL
the	NULL
replacement	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
in	NULL
the	NULL
inverted	NULL
orientation	NULL
was	NULL
also	NULL
infectious	NULL
in	NULL
H9	NULL
cells	NULL
,	NULL
although	NULL
progeny	NULL
virus	NULL
production	NULL
was	NULL
markedly	NULL
delayed	NULL
(	NULL
bottom	NULL
row	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
error-prone	NULL
properties	NULL
of	NULL
the	NULL
HIV	NULL
RT	NULL
,	NULL
nucleotide	NULL
substitutions	NULL
appear	NULL
with	NULL
great	NULL
frequency	NULL
during	NULL
passage	NULL
of	NULL
virus	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
3	NULL
,	NULL
24	NULL
)	NULL
.	NULL

We	NULL
have	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
previously	NULL
reported	NULL
that	NULL
the	NULL
appearance	NULL
of	NULL
virus	NULL
at	NULL
very	NULL
late	NULL
times	NULL
(	NULL
>	NULL
3	NULL
weeks	NULL
)	NULL
following	NULL
infection	NULL
with	NULL
HIV	NULL
mutants	NULL
frequently	NULL
heralds	NULL
the	NULL
emergence	NULL
of	NULL
second-site	NULL
revertants	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
to	NULL
ascertain	NULL
whether	NULL
the	NULL
reconstructed	NULL
LTR	NULL
had	NULL
changed	NULL
during	NULL
some	NULL
of	NULL
the	NULL
prolonged	NULL
replication	NULL
cycles	NULL
,	NULL
viral	NULL
RNA	NULL
was	NULL
purified	NULL
from	NULL
the	NULL
particles	NULL
released	NULL
from	NULL
H9	NULL
cells	NULL
(	NULL
day	NULL
24	NULL
;	NULL
arrowhead	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
that	NULL
had	NULL
been	NULL
previously	NULL
infected	NULL
with	NULL
HIV	NULL
containing	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
and	NULL
was	NULL
analyzed	NULL
by	NULL
RT-PCR	NULL
and	NULL
subsequent	NULL
nucleotide	NULL
sequencing	NULL
.	NULL

No	NULL
changes	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
-204	NULL
to	NULL
-39	NULL
region	NULL
of	NULL
the	NULL
reconstructed	NULL
U3	NULL
LTR	NULL
.	NULL

The	NULL
replication	NULL
of	NULL
HIV	NULL
containing	NULL
the	NULL
inverted	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
continued	NULL
to	NULL
be	NULL
markedly	NULL
retarded	NULL
(	NULL
bottom	NULL
row	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
during	NULL
a	NULL
second	NULL
cycle	NULL
of	NULL
infection	NULL
of	NULL
H9	NULL
cells	NULL
when	NULL
the	NULL
day	NULL
45	NULL
virus	NULL
from	NULL
the	NULL
initial	NULL
infection	NULL
(	NULL
indicated	NULL
by	NULL
the	NULL
arrow	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
was	NULL
used	NULL
as	NULL
the	NULL
inoculum	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
Table	NULL
5	NULL
indicate	NULL
that	NULL
of	NULL
the	NULL
human	NULL
lymphocyte	NULL
cell	NULL
lines	NULL
tested	NULL
,	NULL
AA2	NULL
cells	NULL
were	NULL
the	NULL
most	NULL
susceptible	NULL
to	NULL
infection	NULL
by	NULL
HIVs	NULL
containing	NULL
reconstructed	NULL
enhancer	NULL
or	NULL
E+P	NULL
modules	NULL
.	NULL

Even	NULL
virus	NULL
containing	NULL
an	NULL
inverted	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
or	NULL
an	NULL
MLV	NULL
enhancer	NULL
element	NULL
was	NULL
able	NULL
to	NULL
replicate	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Most	NULL
interestingly	NULL
,	NULL
HIV	NULL
containing	NULL
the	NULL
entire	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
E+P	NULL
module	NULL
in	NULL
place	NULL
of	NULL
HIV	NULL
sequences	NULL
located	NULL
between	NULL
-129	NULL
and	NULL
-1	NULL
(	NULL
which	NULL
includes	NULL
the	NULL
HIV	NULL
NF-KB	NULL
,	NULL
Sp1	NULL
,	NULL
and	NULL
TATA	NULL
elements	NULL
)	NULL
produced	NULL
progeny	NULL
virions	NULL
in	NULL
AA2	NULL
cells	NULL
.	NULL

Molt	NULL
3	NULL
,	NULL
HL60	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
resistant	NULL
to	NULL
infection	NULL
by	NULL
all	NULL
of	NULL
the	NULL
LTR-mutant	NULL
HIVs	NULL
constructed	NULL
for	NULL
this	NULL
study	NULL
.	NULL

DISCUSSION	NULL
RNA	NULL
synthesis	NULL
in	NULL
eukaryotic	NULL
cells	NULL
is	NULL
modulated	NULL
by	NULL
transcription	NULL
activator	NULL
proteins	NULL
which	NULL
bind	NULL
to	NULL
DNA	NULL
motifs	NULL
located	NULL
upstream	NULL
of	NULL
their	NULL
respective	NULL
promoters	NULL
.	NULL

Like	NULL
other	NULL
eukaryotic	NULL
promoters	NULL
,	NULL
the	NULL
HIV	NULL
LTR	NULL
contains	NULL
its	NULL
own	NULL
en	NULL
TABLE	NULL
5	NULL
.	NULL

Time	NULL
required	NULL
for	NULL
peak	NULL
RT	NULL
production	NULL
in	NULL
continuous	NULL
human	NULL
lymphoid	NULL
cell	NULL
lines	NULL
by	NULL
HIVs	NULL
containing	NULL
heterologous	NULL
enhancer/promoter	NULL
elements	NULL
Time	NULL
(	NULL
days	NULL
)	NULL
needed	NULL
for	NULL
peak	NULL
RT	NULL
Construct	NULL
production	NULL
``	NULL
H9	NULL
CEM	NULL
(	NULL
12D7	NULL
)	NULL
AA2	NULL
Wild-type	NULL
HIV-1	NULL
9	NULL
,	NULL
9	NULL
9	NULL
,	NULL
9	NULL
6	NULL
,	NULL
6	NULL
Enhancer	NULL
mutants	NULL
dl	NULL
.	NULL

«	NULL
B/Spl	NULL
-	NULL
-	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
17	NULL
,	NULL
17	NULL
33	NULL
,	NULL
34	NULL
6	NULL
,	NULL
6	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
(	NULL
inverted	NULL
)	NULL
39	NULL
,	NULL
42	NULL
-	NULL
3	NULL
,	NULL
3	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
9	NULL
,	NULL
9	NULL
17	NULL
,	NULL
17	NULL
6	NULL
,	NULL
6	NULL
MLV	NULL
ND	NULL
21	NULL
,	NULL
24	NULL
14	NULL
,	NULL
17	NULL
ND	NULL
ND	NULL
Enhancer/promoter	NULL
mutants	NULL
dl	NULL
.	NULL

«	NULL
B/Spl/TATA	NULL
ND	NULL
ND	NULL
ND	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
/TATA	NULL
-	NULL
ND	NULL
10	NULL
,	NULL
10	NULL
MLV/TATA	NULL
ND	NULL
-	NULL
``	NULL
Results	NULL
from	NULL
two	NULL
experiments	NULL
are	NULL
given	NULL
.	NULL

-	NULL
,	NULL
RT	NULL
activity	NULL
not	NULL
detected	NULL
during	NULL
2	NULL
months	NULL
of	NULL
infection	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

750	NULL
CHANG	NULL
ET	NULL
AL	NULL
.	NULL

semble	NULL
of	NULL
DNA	NULL
elements	NULL
to	NULL
which	NULL
transcriptional	NULL
regulatory	NULL
factors	NULL
bind	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
were	NULL
identified	NULL
from	NULL
mutagenesis	NULL
studies	NULL
of	NULL
LTR-driven	NULL
reporter	NULL
gene	NULL
constructs	NULL
,	NULL
some	NULL
were	NULL
found	NULL
following	NULL
gel	NULL
retardation	NULL
or	NULL
DNA	NULL
footprinting	NULL
experiments	NULL
,	NULL
and	NULL
others	NULL
were	NULL
discovered	NULL
from	NULL
searches	NULL
of	NULL
nucleotide	NULL
sequence	NULL
data	NULL
bases	NULL
.	NULL

Much	NULL
of	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
functional	NULL
roles	NULL
of	NULL
viral	NULL
and	NULL
cellular	NULL
proteins	NULL
that	NULL
regulate	NULL
HIV	NULL
gene	NULL
activity	NULL
has	NULL
come	NULL
from	NULL
transient	NULL
transfection	NULL
experiments	NULL
utilizing	NULL
LTR-reporter	NULL
gene	NULL
constructs	NULL
carried	NULL
out	NULL
primarily	NULL
in	NULL
continuous	NULL
epithelial	NULL
lines	NULL
such	NULL
as	NULL
HeLa	NULL
cells	NULL
.	NULL

Results	NULL
from	NULL
these	NULL
studies	NULL
have	NULL
supported	NULL
models	NULL
of	NULL
viral	NULL
gene	NULL
regulation	NULL
in	NULL
which	NULL
basal	NULL
levels	NULL
of	NULL
expression	NULL
are	NULL
modulated	NULL
following	NULL
the	NULL
induction	NULL
of	NULL
certain	NULL
cellular	NULL
factors	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
NF-KB	NULL
)	NULL
or	NULL
the	NULL
synthesis	NULL
of	NULL
the	NULL
HIV-encoded	NULL
proteins	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
Tat	NULL
or	NULL
Rev	NULL
)	NULL
.	NULL

Tat	NULL
is	NULL
required	NULL
for	NULL
the	NULL
efficient	NULL
production	NULL
of	NULL
progeny	NULL
virions	NULL
.	NULL

Although	NULL
the	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
underlying	NULL
Tat	NULL
transactivation	NULL
has	NULL
engendered	NULL
considerable	NULL
debate	NULL
,	NULL
there	NULL
is	NULL
general	NULL
agreement	NULL
on	NULL
two	NULL
points	NULL
:	NULL
(	NULL
i	NULL
)	NULL
Tat	NULL
increases	NULL
steady-state	NULL
levels	NULL
of	NULL
HIV	NULL
LTR-directed	NULL
transcripts	NULL
,	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
promoter-proximal	NULL
positioning	NULL
of	NULL
Tat	NULL
(	NULL
via	NULL
its	NULL
interaction	NULL
with	NULL
TAR	NULL
)	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

The	NULL
latter	NULL
requirement	NULL
suggests	NULL
but	NULL
does	NULL
not	NULL
prove	NULL
that	NULL
the	NULL
function	NULL
of	NULL
TAR	NULL
may	NULL
be	NULL
only	NULL
to	NULL
deliver	NULL
Tat	NULL
to	NULL
the	NULL
initiation	NULL
complex	NULL
during	NULL
its	NULL
assembly	NULL
,	NULL
where	NULL
it	NULL
might	NULL
interact	NULL
with	NULL
transcriptional	NULL
acti-vators	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
demonstrated	NULL
Tat	NULL
transactivation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TAR	NULL
in	NULL
systems	NULL
in	NULL
which	NULL
Tat	NULL
was	NULL
targeted	NULL
to	NULL
the	NULL
promoter	NULL
as	NULL
a	NULL
chimeric	NULL
protein	NULL
containing	NULL
known	NULL
binding	NULL
sites	NULL
for	NULL
RNA	NULL
(	NULL
52	NULL
,	NULL
57	NULL
)	NULL
or	NULL
DNA	NULL
(	NULL
4	NULL
,	NULL
32	NULL
,	NULL
56	NULL
)	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
that	NULL
an	NULL
HIV	NULL
LTR	NULL
,	NULL
lacking	NULL
upstream	NULL
enhancer	NULL
elements	NULL
,	NULL
is	NULL
not	NULL
responsive	NULL
to	NULL
Tat	NULL
(	NULL
4	NULL
,	NULL
37	NULL
)	NULL
and	NULL
fails	NULL
to	NULL
direct	NULL
progeny	NULL
virion	NULL
production	NULL
when	NULL
present	NULL
as	NULL
a	NULL
component	NULL
of	NULL
full-length	NULL
proviral	NULL
DNA	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Restoration	NULL
of	NULL
homologous	NULL
(	NULL
NF-KB	NULL
or	NULL
Sp1	NULL
[	NULL
37	NULL
]	NULL
)	NULL
or	NULL
heterologous	NULL
(	NULL
Apl	NULL
,	NULL
Oct	NULL
1	NULL
,	NULL
ATF	NULL
,	NULL
or	NULL
USF	NULL
[	NULL
4	NULL
,	NULL
56	NULL
]	NULL
)	NULL
elements	NULL
to	NULL
the	NULL
LTR	NULL
resulted	NULL
in	NULL
Tat-responsive	NULL
reporter	NULL
gene	NULL
expression	NULL
;	NULL
the	NULL
introduction	NULL
of	NULL
an	NULL
Spl	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
motif	NULL
into	NULL
an	NULL
enhancerless	NULL
HIV-1	NULL
LTR	NULL
led	NULL
to	NULL
the	NULL
synthesis	NULL
of	NULL
virus	NULL
particles	NULL
(	NULL
49	NULL
)	NULL
.	NULL

In	NULL
this	NULL
work	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
replacement	NULL
enhancer	NULL
elements	NULL
from	NULL
CMV	NULL
,	NULL
MLV	NULL
,	NULL
or	NULL
Py	NULL
can	NULL
direct	NULL
CAT	NULL
expression	NULL
from	NULL
an	NULL
HIV	NULL
LTR	NULL
lacking	NULL
the	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
three	NULL
Spl	NULL
elements	NULL
.	NULL

In	NULL
some	NULL
assays	NULL
(	NULL
CMV	NULL
enhancers	NULL
)	NULL
,	NULL
the	NULL
final	NULL
augmented	NULL
response	NULL
to	NULL
Tat	NULL
was	NULL
equal	NULL
to	NULL
or	NULL
exceeded	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
LTR	NULL
,	NULL
while	NULL
in	NULL
others	NULL
,	NULL
the	NULL
level	NULL
of	NULL
Tat	NULL
transactivation	NULL
was	NULL
reduced	NULL
(	NULL
MLV	NULL
and	NULL
Py	NULL
enhancers	NULL
)	NULL
or	NULL
undetectable	NULL
(	NULL
MT-1	NULL
)	NULL
.	NULL

This	NULL
result	NULL
was	NULL
not	NULL
unexpected	NULL
in	NULL
view	NULL
of	NULL
the	NULL
previously	NULL
reported	NULL
effects	NULL
of	NULL
heterologous	NULL
enhancers	NULL
on	NULL
HIV	NULL
LTR-directed	NULL
reporter	NULL
gene	NULL
expression	NULL
(	NULL
44	NULL
)	NULL
.	NULL

What	NULL
was	NULL
unanticipated	NULL
,	NULL
however	NULL
,	NULL
was	NULL
the	NULL
restoration	NULL
of	NULL
replication	NULL
competence	NULL
to	NULL
noninfectious	NULL
stocks	NULL
of	NULL
HIV	NULL
by	NULL
heterologous	NULL
enhancers	NULL
.	NULL

As	NULL
noted	NULL
above	NULL
,	NULL
we	NULL
had	NULL
previously	NULL
reported	NULL
that	NULL
a	NULL
cloned	NULL
HIV	NULL
provirus	NULL
containing	NULL
no	NULL
enhancers	NULL
failed	NULL
to	NULL
generate	NULL
virus	NULL
progeny	NULL
and	NULL
that	NULL
the	NULL
inclusion	NULL
of	NULL
a	NULL
single	NULL
NF-	NULL
«	NULL
B	NULL
or	NULL
Sp1	NULL
element	NULL
was	NULL
required	NULL
for	NULL
particle	NULL
production	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
(	NULL
49	NULL
)	NULL
.	NULL

A	NULL
sequence	NULL
analysis	NULL
of	NULL
the	NULL
heterologous	NULL
enhancer	NULL
motifs	NULL
used	NULL
in	NULL
this	NULL
study	NULL
indicated	NULL
that	NULL
the	NULL
MLV	NULL
and	NULL
Py	NULL
enhancer	NULL
replacements	NULL
contained	NULL
no	NULL
sequences	NULL
with	NULL
homology	NULL
to	NULL
either	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
or	NULL
Spl	NULL
element	NULL
.	NULL

However	NULL
,	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
and	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
enhancers	NULL
each	NULL
contain	NULL
copies	NULL
of	NULL
an	NULL
18-bp	NULL
repeat	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
capable	NULL
of	NULL
binding	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
phytohemagglutinin-phorbol	NULL
myristate	NULL
acetate-stimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
demonstrated	NULL
that	NULL
the	NULL
19-bp	NULL
repeat	NULL
of	NULL
the	NULL
CMV-IE	NULL
enhancer	NULL
binds	NULL
Sp1	NULL
;	NULL
however	NULL
,	NULL
mutagenesis	NULL
of	NULL
this	NULL
binding	NULL
site	NULL
failed	NULL
to	NULL
affect	NULL
the	NULL
promoter	NULL
function	NULL
(	NULL
35	NULL
)	NULL
.	NULL

The	NULL
biological	NULL
activity	NULL
of	NULL
HIVs	NULL
containing	NULL
heterologous	NULL
J.	NULL
Viror	NULL
.	NULL

enhancer	NULL
elements	NULL
varied	NULL
greatly	NULL
among	NULL
the	NULL
various	NULL
host	NULL
cells	NULL
used	NULL
for	NULL
infection	NULL
.	NULL

This	NULL
result	NULL
is	NULL
reminiscent	NULL
of	NULL
previously	NULL
reported	NULL
infectivity	NULL
studies	NULL
involving	NULL
HIV-1	NULL
mutants	NULL
deleted	NULL
for	NULL
the	NULL
three	NULL
Sp1	NULL
binding	NULL
sites	NULL
,	NULL
in	NULL
which	NULL
a	NULL
continuum	NULL
of	NULL
virus	NULL
replication	NULL
that	NULL
reflected	NULL
levels	NULL
of	NULL
cellular	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
was	NULL
observed	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Virus	NULL
preparations	NULL
containing	NULL
the	NULL
CMV-IE	NULL
enhancer	NULL
substitutions	NULL
uniformly	NULL
exhibited	NULL
the	NULL
highest	NULL
infectivities	NULL
in	NULL
activated	NULL
human	NULL
PBLs	NULL
,	NULL
replicating	NULL
with	NULL
kinetics	NULL
quite	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
wild-type	NULL
HIV	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

In	NULL
continuous	NULL
human	NULL
T-cell	NULL
lines	NULL
,	NULL
an	NULL
apparent	NULL
hierarchy	NULL
[	NULL
wild-type	NULL
HIV	NULL
>	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
>	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
>	NULL
MLV	NULL
]	NULL
of	NULL
virus	NULL
replication	NULL
capacities	NULL
was	NULL
observed	NULL
,	NULL
perhaps	NULL
indicative	NULL
of	NULL
the	NULL
relative	NULL
strengths	NULL
of	NULL
the	NULL
reconstructed	NULL
enhancer/promoters	NULL
.	NULL

This	NULL
difference	NULL
in	NULL
virus	NULL
infectivity	NULL
was	NULL
more	NULL
pronounced	NULL
in	NULL
H9	NULL
and	NULL
CEM	NULL
cells	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
,	NULL
in	NULL
which	NULL
the	NULL
replication	NULL
of	NULL
HIV	NULL
containing	NULL
the	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
element	NULL
consistently	NULL
lagged	NULL
behind	NULL
replication	NULL
of	NULL
virus	NULL
with	NULL
the	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
enhancer	NULL
.	NULL

Although	NULL
we	NULL
can	NULL
provide	NULL
no	NULL
mechanistic	NULL
explanation	NULL
for	NULL
this	NULL
result	NULL
,	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
more	NULL
active	NULL
CMV-IE	NULL
(	NULL
b	NULL
)	NULL
element	NULL
includes	NULL
an	NULL
element	NULL
(	NULL
18*	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
with	NULL
Apl	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
[	NULL
missing	NULL
from	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
]	NULL
and	NULL
lacks	NULL
the	NULL
21-bp	NULL
motif	NULL
present	NULL
in	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
.	NULL

The	NULL
infectivity	NULL
of	NULL
HIV	NULL
containing	NULL
a	NULL
substituted	NULL
MLV	NULL
enhancer	NULL
could	NULL
be	NULL
demonstrated	NULL
only	NULL
in	NULL
AA2	NULL
cells	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
originally	NULL
derived	NULL
from	NULL
the	NULL
CD4*	NULL
B-cell	NULL
line	NULL
WIL-2	NULL
and	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
exquisitely	NULL
sensitive	NULL
to	NULL
HIV-1	NULL
infection	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Although	NULL
not	NULL
commonly	NULL
used	NULL
for	NULL
infectivity	NULL
studies	NULL
,	NULL
AA2	NULL
cells	NULL
generate	NULL
up	NULL
to	NULL
100-fold	NULL
more	NULL
virus	NULL
than	NULL
do	NULL
CEM	NULL
cells	NULL
and	NULL
undergo	NULL
extremely	NULL
rapid	NULL
cytopathic	NULL
effect	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
5	NULL
,	NULL
AA2Z	NULL
cells	NULL
were	NULL
also	NULL
permissive	NULL
for	NULL
HIV	NULL
containing	NULL
the	NULL
inverted	NULL
CMV-IE	NULL
(	NULL
a	NULL
)	NULL
enhancer	NULL
as	NULL
well	NULL
as	NULL
for	NULL
virus	NULL
with	NULL
the	NULL
CMV	NULL
enhancer	NULL
plus	NULL
the	NULL
CMV	NULL
TATA	NULL
elements	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
previously	NULL
reported	NULL
studies	NULL
that	NULL
have	NULL
evaluated	NULL
the	NULL
role	NULL
of	NULL
upstream	NULL
regulatory	NULL
elements	NULL
on	NULL
retroviral	NULL
tropism	NULL
,	NULL
infectivity	NULL
,	NULL
and	NULL
cytopathic	NULL
ity	NULL
.	NULL

For	NULL
example	NULL
,	NULL
it	NULL
is	NULL
now	NULL
recognized	NULL
from	NULL
work	NULL
involving	NULL
Friend	NULL
and	NULL
Moloney	NULL
MLVs	NULL
that	NULL
cis-acting	NULL
sequences	NULL
,	NULL
located	NULL
in	NULL
the	NULL
U3	NULL
region	NULL
of	NULL
their	NULL
respective	NULL
LTRs	NULL
,	NULL
are	NULL
the	NULL
major	NULL
determinants	NULL
of	NULL
whether	NULL
these	NULL
retroviruses	NULL
induce	NULL
an	NULL
erythroleukemia	NULL
or	NULL
a	NULL
lymphocytic	NULL
leukemia/lymphoma	NULL
(	NULL
10	NULL
)	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
replacement	NULL
of	NULL
the	NULL
Moloney	NULL
MLV	NULL
enhancer	NULL
with	NULL
a	NULL
Py	NULL
regulatory	NULL
element	NULL
results	NULL
in	NULL
a	NULL
nonpathogenic	NULL
virus	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
human	NULL
retroviruses	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
sequences	NULL
located	NULL
upstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
II	NULL
(	NULL
HTLV-II	NULL
)	NULL
limit	NULL
expression	NULL
to	NULL
human	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
;	NULL
no	NULL
HTLV-II-directed	NULL
RNA	NULL
was	NULL
detected	NULL
in	NULL
several	NULL
human	NULL
epithelial	NULL
and	NULL
fibroblast	NULL
cell	NULL
lines	NULL
(	NULL
11	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
functional	NULL
studies	NULL
evaluating	NULL
HIV-1	NULL
LTR-directed	NULL
gene	NULL
activity	NULL
thus	NULL
far	NULL
indicate	NULL
little	NULL
if	NULL
any	NULL
cell	NULL
type	NULL
or	NULL
species	NULL
restriction	NULL
imposed	NULL
by	NULL
elements	NULL
located	NULL
in	NULL
U3	NULL
.	NULL

This	NULL
very	NULL
likely	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
experiments	NULL
evaluating	NULL
HIV	NULL
LTR	NULL
function	NULL
have	NULL
all	NULL
been	NULL
conducted	NULL
in	NULL
tissue	NULL
culture	NULL
systems	NULL
.	NULL

The	NULL
physiological	NULL
role	NULL
(	NULL
s	NULL
)	NULL
of	NULL
the	NULL
multiple	NULL
regulatory	NULL
motifs	NULL
as	NULL
well	NULL
as	NULL
the	NULL
possibility	NULL
that	NULL
HIV	NULL
LTR-directed	NULL
expression	NULL
may	NULL
be	NULL
restricted	NULL
to	NULL
or	NULL
modulated	NULL
in	NULL
certain	NULL
subsets	NULL
of	NULL
the	NULL
lymphocyte/monocyte	NULL
lineage	NULL
remain	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Alicia	NULL
J.	NULL
Buckler-White	NULL
for	NULL
oligonucleotide	NULL
synthesis	NULL
,	NULL
Chuck	NULL
Buckler	NULL
for	NULL
assistance	NULL
with	NULL
computer	NULL
analysis	NULL
,	NULL
K.-T.	NULL
Jeang	NULL
,	NULL
R.	NULL
Repaske	NULL
,	NULL
M.	NULL
Stinski	NULL
,	NULL
S.	NULL
Venkatesan	NULL
,	NULL
G.	NULL
Englund	NULL
,	NULL
and	NULL
D.	NULL
Hoggan	NULL
Vor	NULL
.	NULL

67	NULL
,	NULL
1993	NULL
for	NULL
supplying	NULL
plasmids	NULL
and	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
J	NULL
.	NULL

Silver	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
for	NULL
critical	NULL
reviews	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

REFERENCES	NULL
.	NULL

Adachi	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
E.	NULL
Gendelman	NULL
,	NULL
S.	NULL
Koenig	NULL
,	NULL
T.	NULL
Folks	NULL
,	NULL
R.	NULL
Willey	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1986	NULL
.	NULL

Production	NULL
of	NULL
acquired	NULL
immunodeficiency	NULL
syndrome-associated	NULL
retrovirus	NULL
in	NULL
human	NULL
and	NULL
nonhuman	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
infectious	NULL
molecular	NULL
clone	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

59:284-291.	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
C.	NULL
Guo	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1985	NULL
.	NULL

Transactivator	NULL
gene	NULL
of	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
III	NULL
(	NULL
HTLV-III	NULL
)	NULL
.	NULL

Science	NULL
229:69-73.	NULL
.	NULL

Bebenek	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
Abbotts	NULL
,	NULL
J.	NULL
D.	NULL
Roberts	NULL
,	NULL
S.	NULL
H.	NULL
Wilson	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Kunkel	NULL
.	NULL

1989	NULL
.	NULL

Specificity	NULL
and	NULL
mechanism	NULL
of	NULL
error-prone	NULL
replication	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
reverse	NULL
transcriptase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:16948-16956.	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
A.	NULL
Gatignol	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1990	NULL
.	NULL

TAR-independent	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
:	NULL
evidence	NULL
that	NULL
Tat	NULL
requires	NULL
specific	NULL
regions	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

Cell	NULL
62:757-767.	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
roles	NULL
for	NULL
the	NULL
TATA	NULL
promoter	NULL
and	NULL
enhancers	NULL
in	NULL
basal	NULL
and	NULL
Tat-induced	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:139-149.	NULL
.	NULL

Boshart	NULL
,	NULL
M.	NULL
,	NULL
F.	NULL
Weber	NULL
,	NULL
G.	NULL
Jahn	NULL
,	NULL
K.	NULL
Dorsch-Hasler	NULL
,	NULL
B.	NULL
Flecken-	NULL
stein	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
very	NULL
strong	NULL
enhancer	NULL
is	NULL
located	NULL
upstream	NULL
of	NULL
an	NULL
immediate	NULL
early	NULL
gene	NULL
of	NULL
human	NULL
cytomegalovi-rus	NULL
.	NULL

Cell	NULL
41:521-530.	NULL
.	NULL

Campbell	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
L.	NULL
P.	NULL
Villarreal	NULL
.	NULL

1988	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
the	NULL
individual	NULL
enhancer	NULL
core	NULL
sequences	NULL
of	NULL
polyoma	NULL
virus	NULL
:	NULL
cell-specific	NULL
uncoupling	NULL
of	NULL
DNA	NULL
replication	NULL
from	NULL
transcription	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1993-2004.	NULL
.	NULL

Chaffee	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
M.	NULL
Leeds	NULL
,	NULL
T.	NULL
J.	NULL
Mathews	NULL
,	NULL
K.	NULL
J.	NULL
Weinhold	NULL
,	NULL
M.	NULL
Skinner	NULL
,	NULL
D.	NULL
P.	NULL
Bolognesi	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Hershfield	NULL
.	NULL

1988	NULL
.	NULL

Phenotypic	NULL
variation	NULL
in	NULL
the	NULL
response	NULL
to	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
among	NULL
derivatives	NULL
of	NULL
the	NULL
CEM	NULL
T	NULL
and	NULL
WIL-2	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

168:605-621.	NULL
.	NULL

Chang	NULL
,	NULL
L.-J	NULL
.	NULL

,	NULL
R.	NULL
Hirsch	NULL
,	NULL
D.	NULL
Ganem	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Varmus	NULL
.	NULL

1990	NULL
.	NULL

Effects	NULL
of	NULL
insertional	NULL
and	NULL
point	NULL
mutations	NULL
on	NULL
the	NULL
functions	NULL
of	NULL
the	NULL
duck	NULL
hepatitis	NULL
B	NULL
virus	NULL
polymerase	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5553-5558	NULL
.	NULL

Chatis	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
C.	NULL
A.	NULL
Holland	NULL
,	NULL
J.	NULL
W.	NULL
Hartley	NULL
,	NULL
W.	NULL
P.	NULL
Rowe	NULL
,	NULL
and	NULL
N.	NULL
Hopkins	NULL
.	NULL

1983	NULL
.	NULL

Role	NULL
for	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
genome	NULL
in	NULL
determining	NULL
disease	NULL
specificity	NULL
of	NULL
Friend	NULL
and	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
viruses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
80:4408-4411	NULL
.	NULL

Chen	NULL
,	NULL
I.	NULL
S.	NULL
Y.	NULL
,	NULL
J.	NULL
McLaughlin	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Golde	NULL
.	NULL

1984	NULL
.	NULL

Long	NULL
terminal	NULL
repeats	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
II	NULL
genome	NULL
determines	NULL
target	NULL
cell	NULL
specificity	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
309:276-279	NULL
.	NULL

Clark	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
R.	NULL
Mathews	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hay	NULL
.	NULL

1990	NULL
.	NULL

Interaction	NULL
of	NULL
enhancer-binding	NULL
protein	NULL
EBP1	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
with	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
enhancer	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1335-1344	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1986	NULL
.	NULL

Trans-activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
occurs	NULL
via	NULL
a	NULL
bimodal	NULL
mechanism	NULL
.	NULL

Cell	NULL
46:973-982	NULL
.	NULL

Davis	NULL
,	NULL
B.	NULL
,	NULL
E.	NULL
Linney	NULL
,	NULL
and	NULL
H.	NULL
Fan	NULL
.	NULL

1985	NULL
.	NULL

Suppression	NULL
of	NULL
leukemia	NULL
virus	NULL
pathogenicity	NULL
by	NULL
polyoma	NULL
virus	NULL
enhancers	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
314:550-553	NULL
.	NULL

Dayton	NULL
,	NULL
A.	NULL
I.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
E.	NULL
C.	NULL
Goh	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
trans-activator	NULL
gene	NULL
of	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
III	NULL
is	NULL
required	NULL
for	NULL
replication	NULL
.	NULL

Cell	NULL
44:941-947	NULL
.	NULL

Feinberg	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Frankel	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Tat	NULL
in	NULL
the	NULL
immunodeficiency	NULL
virus	NULL
life	NULL
cycle	NULL
indicates	NULL
a	NULL
primary	NULL
effect	NULL
on	NULL
transcriptional	NULL
elongation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:4045-4049	NULL
.	NULL

Fisher	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
M.	NULL
B.	NULL
Feinberg	NULL
,	NULL
S.	NULL
A.	NULL
Josephs	NULL
,	NULL
M.	NULL
E.	NULL
Harper	NULL
,	NULL
L.	NULL
M.	NULL
Marselle	NULL
,	NULL
G.	NULL
Reyes	NULL
,	NULL
M.	NULL
A.	NULL
Gonda	NULL
,	NULL
A.	NULL
Aldovini	NULL
,	NULL
C.	NULL
Debouk	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
frans-activator	NULL
gene	NULL
of	NULL
HTLV-III	NULL
is	NULL
essential	NULL
for	NULL
virus	NULL
replication	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
320:367-371	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Benn	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
T.	NULL
Theodore	NULL
,	NULL
M.	NULL
D.	NULL
Hoggan	NULL
,	NULL
M.	NULL
Martin	NULL
,	NULL
M.	NULL
Lightfoote	NULL
,	NULL
and	NULL
K.	NULL
Sell	NULL
.	NULL

1985	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
continuous	NULL
T-cell	NULL
line	NULL
susceptible	NULL
to	NULL
the	NULL
cytopathic	NULL
effects	NULL
of	NULL
the	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
associated	NULL
retro-virus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:4539-4543	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
E.	NULL
Soultanakis	NULL
,	NULL
F.	NULL
K.	NULL
Wu	NULL
,	NULL
R.	NULL
HETEROLOGOUS	NULL
ENHANCER/PROMOTER-CONTAINING	NULL
HIVs	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

751	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
LTR	NULL
TATA	NULL
and	NULL
TAR	NULL
region	NULL
sequences	NULL
required	NULL
for	NULL
transcription	NULL
regulation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:765-778	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
F.	NULL
K.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1987	NULL
.	NULL

Interactions	NULL
of	NULL
cellular	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:3761-3770	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

Graham	NULL
,	NULL
F.	NULL
L.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
van	NULL
der	NULL
Eb	NULL
.	NULL

1973	NULL
.	NULL

A	NULL
new	NULL
technique	NULL
for	NULL
the	NULL
assay	NULL
of	NULL
infectivity	NULL
of	NULL
human	NULL
adenovirus	NULL
5	NULL
DNA	NULL
.	NULL

Virology	NULL
52:456-467.	NULL
.	NULL

Greene	NULL
,	NULL
W.	NULL
C.	NULL
1990	NULL
.	NULL

Regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:453-475	NULL
.	NULL

Hahn	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
G.	NULL
M.	NULL
Shaw	NULL
,	NULL
M.	NULL
E.	NULL
Taylor	NULL
,	NULL
R.	NULL
R.	NULL
Redfield	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
E.	NULL
S.	NULL
Parks	NULL
,	NULL
and	NULL
W.	NULL
P.	NULL
Parks	NULL
.	NULL

1986	NULL
.	NULL

Genetic	NULL
variation	NULL
in	NULL
HTLV-III/	NULL
LAV	NULL
over	NULL
time	NULL
in	NULL
patients	NULL
with	NULL
AIDS	NULL
or	NULL
at	NULL
risk	NULL
for	NULL
AIDS	NULL
.	NULL

Science	NULL
232:1548-1553.	NULL
.	NULL

Harada	NULL
,	NULL
S.	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
H.	NULL
Nakashima	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
and	NULL
N.	NULL
Yamamoto	NULL
.	NULL

1986	NULL
.	NULL

Tumor	NULL
promoter	NULL
,	NULL
TPA	NULL
,	NULL
enhances	NULL
replication	NULL
of	NULL
HTLV-III/LAV	NULL
.	NULL

Virology	NULL
154:249-258	NULL
.	NULL

Harrich	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
F.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
J.	NULL
Gonzalez	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1989	NULL
.	NULL

Role	NULL
of	NULL
Spl-binding	NULL
domains	NULL
in	NULL
in	NULL
vivo	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:2585-2591	NULL
.	NULL

Hauber	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
B.	NULL
R.	NULL
Cullen	NULL
.	NULL

1988	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
trans-activation	NULL
responsive	NULL
region	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:673-679.	NULL
.	NULL

Hunninghake	NULL
,	NULL
G.	NULL
W.	NULL
,	NULL
M.	NULL
M.	NULL
Monick	NULL
,	NULL
B.	NULL
Liu	NULL
,	NULL
and	NULL
M.	NULL
F.	NULL
Stinski	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
promoter	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
major	NULL
immediate-early	NULL
gene	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
responds	NULL
to	NULL
T-lymphocyte	NULL
stimulation	NULL
and	NULL
contains	NULL
functional	NULL
cyclic	NULL
AMP-responsive	NULL
elements	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3026-3033	NULL
.	NULL

Israel	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
D.	NULL
T.	NULL
Simmons	NULL
,	NULL
S.	NULL
L.	NULL
Hourihan	NULL
,	NULL
W.	NULL
P.	NULL
Row	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1979	NULL
.	NULL

Interrupting	NULL
the	NULL
early	NULL
region	NULL
of	NULL
polyoma	NULL
virus	NULL
DNA	NULL
enhances	NULL
tumorigenicity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
76:3713-3716	NULL
.	NULL

Jakobovits	NULL
,	NULL
A.	NULL
,	NULL
D.	NULL
H.	NULL
Smith	NULL
,	NULL
E.	NULL
B.	NULL
Jakobovits	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Capon	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
discrete	NULL
element	NULL
3	NULL
'	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
and	NULL
HIV-2	NULL
mRNA	NULL
initiation	NULL
sites	NULL
mediates	NULL
transcriptional	NULL
activation	NULL
by	NULL
an	NULL
HIV	NULL
frans-activator	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:255-261	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
J.	NULL
T.	NULL
Kadonaga	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1986	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
AIDS	NULL
retrovirus	NULL
promoter	NULL
by	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
,	NULL
Spl	NULL
.	NULL

Science	NULL
232:755-759	NULL
.	NULL

Kamine	NULL
,	NULL
J.	NULL
,	NULL
T.	NULL
Subramanian	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1991	NULL
.	NULL

Spl-dependent	NULL
activation	NULL
of	NULL
a	NULL
synthetic	NULL
promoter	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
8:8510-8514	NULL
.	NULL

Kao	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
A.	NULL
F.	NULL
Calman	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1987	NULL
.	NULL

Antitermination	NULL
of	NULL
transcription	NULL
within	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
HIV-1	NULL
by	NULL
tat	NULL
gene	NULL
product	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
330:489-493	NULL
.	NULL

Kunkel	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

1985	NULL
.	NULL

Rapid	NULL
and	NULL
efficient	NULL
site-specific	NULL
mutagenesis	NULL
without	NULL
phenotypic	NULL
selection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:488-492	NULL
.	NULL

Lang	NULL
,	NULL
D.	NULL
,	NULL
H.	NULL
Fickenscher	NULL
,	NULL
and	NULL
T.	NULL
Stamminger	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
proximal	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
IE-1/2	NULL
enhancer/promoter	NULL
reveals	NULL
that	NULL
both	NULL
consensus	NULL
and	NULL
aberrant	NULL
recognition	NULL
sequences	NULL
for	NULL
transcription	NULL
factors	NULL
Spl	NULL
and	NULL
CREB	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:3287-3295	NULL
.	NULL

Laspia	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
A.	NULL
P.	NULL
Rice	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Mathews	NULL
.	NULL

1990	NULL
.	NULL

Synergy	NULL
between	NULL
HIV-1	NULL
Tat	NULL
and	NULL
adenovirus	NULL
ElA	NULL
is	NULL
principally	NULL
due	NULL
to	NULL
stabilization	NULL
of	NULL
transcriptional	NULL
elongation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:2397-2408	NULL
.	NULL

Leonard	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Parrott	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
W.	NULL
Turner	NULL
,	NULL
E.	NULL
K.	NULL
Ross	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
NF-kB	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
are	NULL
not	NULL
required	NULL
for	NULL
virus	NULL
infectivity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4919-4924	NULL
.	NULL

Marciniak	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
B.	NULL
J.	NULL
Calnan	NULL
,	NULL
A.	NULL
D.	NULL
Frankel	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
Tat	NULL
protein	NULL
frans-activates	NULL
transcription	NULL
in	NULL
vifro	NULL
.	NULL

752	NULL
39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

CHANG	NULL
ET	NULL
AL	NULL
.	NULL

Cell	NULL
63:791-802	NULL
.	NULL

Meltzer	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
P.	NULL
K.	NULL
Wood	NULL
,	NULL
L.	NULL
Johnson	NULL
,	NULL
and	NULL
S.	NULL
W.	NULL
Needleman	NULL
.	NULL

1990	NULL
.	NULL

Sequencing	NULL
products	NULL
of	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
directly	NULL
without	NULL
purification	NULL
.	NULL

BioTechniques	NULL
8:142-148	NULL
.	NULL

Muesing	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
D.	NULL
H.	NULL
Smith	NULL
,	NULL
and	NULL
D.	NULL
J.	NULL
Capon	NULL
.	NULL

1987	NULL
.	NULL

Regulation	NULL
of	NULL
mRNA	NULL
accumulation	NULL
by	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
trans-activator	NULL
protein	NULL
.	NULL

Cell	NULL
48:691-701	NULL
.	NULL

Myers	NULL
,	NULL
G.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
retroviruses	NULL
and	NULL
AIDS	NULL
1988	NULL
.	NULL

Los	NULL
Alamos	NULL
National	NULL
Laboratory	NULL
,	NULL
Los	NULL
Alamos	NULL
,	NULL
N.	NULL
Mex	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Nakajima	NULL
,	NULL
N.	NULL
,	NULL
M.	NULL
Horikoshi	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1988	NULL
.	NULL

Factors	NULL
involved	NULL
in	NULL
specific	NULL
transcription	NULL
by	NULL
mammalian	NULL
RNA	NULL
polymerase	NULL
H	NULL
:	NULL
purification	NULL
,	NULL
genetics	NULL
specificity	NULL
and	NULL
TATA	NULL
box-promoter	NULL
interactions	NULL
of	NULL
TFIID	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:4028-4040.	NULL
.	NULL

Peterlin	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
P.	NULL
J.	NULL
Barr	NULL
,	NULL
and	NULL
M.	NULL
D.	NULL
Walker	NULL
.	NULL

1986	NULL
.	NULL

Elevated	NULL
levels	NULL
of	NULL
mRNA	NULL
can	NULL
account	NULL
for	NULL
the	NULL
transactivation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:9734-9738	NULL
.	NULL

Popovic	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
G.	NULL
Sarnagadharan	NULL
,	NULL
E.	NULL
Read	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1984	NULL
.	NULL

Detection	NULL
,	NULL
isolation	NULL
,	NULL
and	NULL
continuous	NULL
production	NULL
of	NULL
cytopathic	NULL
retroviruses	NULL
(	NULL
HTLV-III	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
and	NULL
pre-AIDS	NULL
.	NULL

Science	NULL
224:497-500	NULL
.	NULL

Repaske	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
W.	NULL
Hartley	NULL
,	NULL
M.	NULL
F.	NULL
Kavlick	NULL
,	NULL
R.	NULL
R.	NULL
O'Neill	NULL
,	NULL
and	NULL
J	NULL
.	NULL

B.	NULL
Austin	NULL
.	NULL

1989	NULL
.	NULL

Inhibition	NULL
of	NULL
RNase	NULL
H	NULL
activity	NULL
and	NULL
viral	NULL
replication	NULL
by	NULL
single	NULL
mutations	NULL
in	NULL
the	NULL
3°	NULL
region	NULL
of	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1460-1464	NULL
.	NULL

Rice	NULL
,	NULL
A.	NULL
P.	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Mathews	NULL
.	NULL

1988	NULL
.	NULL

Transcriptional	NULL
but	NULL
not	NULL
translational	NULL
regulation	NULL
of	NULL
HIV-1	NULL
by	NULL
the	NULL
tat	NULL
gene	NULL
product	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
332:551-553	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

Location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
III	NULL
(	NULL
HTLVIII/LAV	NULL
)	NULL
long	NULL
terminal	NULL
re	NULL
49	NULL
.	NULL

50	NULL
.	NULL

S1	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

J.	NULL
Viror	NULL
.	NULL

peat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Ross	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
G.	NULL
Englund	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1991	NULL
.	NULL

Contribution	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Spl	NULL
binding	NULL
motifs	NULL
to	NULL
the	NULL
replicative	NULL
capacity	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
distinct	NULL
patterns	NULL
of	NULL
viral	NULL
growth	NULL
are	NULL
determined	NULL
by	NULL
T-cell	NULL
types	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4350-4358	NULL
.	NULL

Sambucetti	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
J.	NULL
M.	NULL
Cherrington	NULL
,	NULL
G.	NULL
W.	NULL
G.	NULL
Wilkinson	NULL
,	NULL
and	NULL
E.	NULL
S.	NULL
Mocarski	NULL
.	NULL

1989	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
activation	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
enhancer	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
viral	NULL
transactivator	NULL
and	NULL
by	NULL
T	NULL
cell	NULL
stimulation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:4251-4258	NULL
.	NULL

Selby	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
E.	NULL
S.	NULL
Bain	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1989	NULL
.	NULL

Structure	NULL
,	NULL
sequence	NULL
,	NULL
and	NULL
position	NULL
of	NULL
the	NULL
stem-loop	NULL
in	NULL
TAR	NULL
determine	NULL
transcription	NULL
elongation	NULL
by	NULL
Tat	NULL
through	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:547-558	NULL
.	NULL

Selby	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1990	NULL
.	NULL

Trans-activation	NULL
by	NULL
HIV-1	NULL
Tat	NULL
via	NULL
a	NULL
RNA	NULL
binding	NULL
protein	NULL
.	NULL

Cell	NULL
62:769-776	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Inducibility	NULL
of	NULL
k	NULL
immunoglob-ulin	NULL
enhancer-binding	NULL
protein	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
a	NULL
post-translational	NULL
mechanism	NULL
.	NULL

Cell	NULL
47:921-928	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
P.	NULL
J.	NULL
Ultz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Sodroski	NULL
,	NULL
J.	NULL
,	NULL
R.	NULL
Patarca	NULL
,	NULL
C.	NULL
Rosen	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

Location	NULL
of	NULL
the	NULL
frans-activating	NULL
region	NULL
on	NULL
the	NULL
genome	NULL
of	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
III	NULL
.	NULL

Science	NULL
229:74-77	NULL
.	NULL

Southgate	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
activates	NULL
transcription	NULL
from	NULL
an	NULL
upstream	NULL
DNA-binding	NULL
site	NULL
:	NULL
implications	NULL
for	NULL
Tat	NULL
function	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:2496-2507	NULL
.	NULL

Southgate	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
M.	NULL
L.	NULL
Zapp	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
.	NULL

1990	NULL
.	NULL

Activation	NULL
of	NULL
transcription	NULL
by	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
tethered	NULL
to	NULL
nascent	NULL
RNA	NULL
through	NULL
another	NULL
protein	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
345:640-642	NULL
.	NULL

Wu	NULL
,	NULL
F.	NULL
K.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Garcia	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1988	NULL
.	NULL

Purification	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
enhancer	NULL
and	NULL
TAR	NULL
binding	NULL
proteins	NULL
EBP-1	NULL
and	NULL
UBP-1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:2117-2129	NULL
.	NULL

